<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">J Child Adolesc Psychopharmacol</journal-id><journal-id journal-id-type="iso-abbrev">J Child Adolesc Psychopharmacol</journal-id><journal-id journal-id-type="publisher-id">cap</journal-id><journal-title-group><journal-title>Journal of Child and Adolescent Psychopharmacology</journal-title></journal-title-group><issn pub-type="ppub">1044-5463</issn><issn pub-type="epub">1557-8992</issn><publisher><publisher-name>Mary Ann Liebert, Inc.</publisher-name><publisher-loc>140 Huguenot Street, 3rd FloorNew Rochelle, NY 10801USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28816509</article-id><article-id pub-id-type="pmc">5771539</article-id><article-id pub-id-type="publisher-id">10.1089/cap.2017.0053</article-id><article-id pub-id-type="doi">10.1089/cap.2017.0053</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Articles</subject></subj-group></article-categories><title-group><article-title>SHP465 Mixed Amphetamine Salts in the Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents: Results of a Randomized, Double-Blind Placebo-Controlled Study</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Brams</surname><given-names>Matthew</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Childress</surname><given-names>Ann C.</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Greenbaum</surname><given-names>Michael</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Yu</surname><given-names>Ming</given-names></name><degrees>MD, PhD</degrees><xref ref-type="aff" rid="aff4"><sup>4</sup></xref></contrib><contrib contrib-type="author"><name><surname>Yan</surname><given-names>Brian</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="aff4"><sup>4</sup></xref></contrib><contrib contrib-type="author"><name><surname>Jaffee</surname><given-names>Margo</given-names></name><degrees>BS</degrees><xref ref-type="aff" rid="aff4"><sup>4</sup></xref></contrib><contrib contrib-type="author"><name><surname>Robertson</surname><given-names>Brigitte</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff4"><sup>4</sup></xref></contrib><aff id="aff1"><label><sup>1</sup></label><institution>Baylor College of Medicine</institution>, Houston, Texas.</aff><aff id="aff2"><label><sup>2</sup></label><institution>Center for Psychiatry and Behavioral Medicine</institution>, Las Vegas, Nevada.</aff><aff id="aff3"><label><sup>3</sup></label><institution>Capstone Clinical Research Center</institution>, Libertyville, Illinois.</aff><aff id="aff4"><label><sup>4</sup></label>Shire, <institution>Lexington</institution>, Massachusetts.</aff></contrib-group><author-notes><fn id="fn1" fn-type="other"><p><bold>Funding:</bold> This clinical research was funded by Shire Development, LLC (Lexington, MA). Shire also provided funding to Complete Healthcare Communications, LLC (West Chester, PA), for support in writing and editing this article.</p></fn><corresp><addr-line>Address correspondence to:</addr-line><addr-line><italic>Matthew Brams, MD</italic></addr-line><institution><italic>Baylor College of Medicine</italic></institution><addr-line><italic>550 Westcott, Suite 310</italic></addr-line><addr-line><italic>Houston, TX 77007</italic></addr-line><italic>E-mail:</italic><email xlink:href="mailto:drmattbrams@aol.com">drmattbrams@aol.com</email></corresp></author-notes><pub-date pub-type="ppub"><day>01</day><month>2</month><year>2018</year></pub-date><pub-date pub-type="epub"><day>01</day><month>2</month><year>2018</year></pub-date><pub-date pub-type="pmc-release"><day>01</day><month>2</month><year>2018</year></pub-date><volume>28</volume><issue>1</issue><fpage>19</fpage><lpage>28</lpage><permissions><copyright-statement>© Matthew Brams et al. 2017; Published by Mary Ann Liebert, Inc.</copyright-statement><copyright-year>2017</copyright-year><license license-type="open-access"><license-p>This article is available under the Creative Commons License CC-BY-NC (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/4.0">http://creativecommons.org/licenses/by-nc/4.0</ext-link>). This license permits non-commercial use, distribution and reproduction in any medium, provided the original work is properly cited. Permission only needs to be obtained for commercial use and can be done via RightsLink.</license-p></license></permissions><self-uri content-type="pdf" xlink:type="simple" xlink:href="cap.2017.0053.pdf"></self-uri><abstract><title><offsets xml_i="5048" xml_f="5056" txt_i="11" txt_f="19">Abstract</offsets></title><p><bold><italic><offsets xml_i="5081" xml_f="5091" txt_i="20" txt_f="30">Objective:</offsets></italic></bold><offsets xml_i="5107" xml_f="5306" txt_i="30" txt_f="229"> The aim of this study was to evaluate the efficacy, safety, and tolerability of SHP465 mixed amphetamine salts (MAS) in children and adolescents with attention-deficit/hyperactivity disorder (ADHD).</offsets></p><p><bold><italic><offsets xml_i="5327" xml_f="5335" txt_i="230" txt_f="238">Methods:</offsets></italic></bold><offsets xml_i="5351" xml_f="5461" txt_i="238" txt_f="348"> This randomized, double-blind dose-optimization study enrolled children and adolescents (6–17 years) meeting </offsets><italic><offsets xml_i="5469" xml_f="5553" txt_i="348" txt_f="432">Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision</offsets></italic><offsets xml_i="5562" xml_f="6131" txt_i="432" txt_f="1001"> ADHD criteria and having baseline ADHD Rating Scale IV (ADHD-RS-IV) total scores ≥28. Participants were randomized 1:1 to placebo or dose-optimized SHP465 MAS (12.5–25 mg) for 4 weeks. Total score change (baseline to week 4) on the ADHD-RS-IV (primary endpoint) and the Clinical Global Impressions-Improvement (CGI-I) scale score at week 4 (key secondary endpoint) were assessed using linear mixed-effects models for repeated measures. Safety and tolerability assessments (secondary endpoints) included treatment-emergent adverse events (TEAEs) and vital sign changes.</offsets></p><p><bold><italic><offsets xml_i="6152" xml_f="6160" txt_i="1002" txt_f="1010">Results:</offsets></italic></bold><offsets xml_i="6176" xml_f="6218" txt_i="1010" txt_f="1052"> Of 264 randomized participants (placebo, </offsets><italic><offsets xml_i="6226" xml_f="6227" txt_i="1052" txt_f="1053">n</offsets></italic><offsets xml_i="6236" xml_f="6256" txt_i="1053" txt_f="1073"> = 132; SHP465 MAS, </offsets><italic><offsets xml_i="6264" xml_f="6265" txt_i="1073" txt_f="1074">n</offsets></italic><offsets xml_i="6274" xml_f="6297" txt_i="1074" txt_f="1097"> = 132), 234 (placebo, </offsets><italic><offsets xml_i="6305" xml_f="6306" txt_i="1097" txt_f="1098">n</offsets></italic><offsets xml_i="6315" xml_f="6335" txt_i="1098" txt_f="1118"> = 118; SHP465 MAS, </offsets><italic><offsets xml_i="6343" xml_f="6344" txt_i="1118" txt_f="1119">n</offsets></italic><offsets xml_i="6353" xml_f="6577" txt_i="1119" txt_f="1343"> = 116) completed the study. The least squares mean (95% confidence interval) treatment difference significantly favored SHP465 MAS over placebo for ADHD-RS-IV total score change from baseline to week 4 (−9.9 [−13.0, −6.8]; </offsets><italic><offsets xml_i="6585" xml_f="6586" txt_i="1343" txt_f="1344">p</offsets></italic><offsets xml_i="6595" xml_f="6674" txt_i="1344" txt_f="1420"> &lt; 0.001; effect size = 0.80) and CGI-I score at week 4 (−0.8 [−1.1, −0.5]; </offsets><italic><offsets xml_i="6682" xml_f="6683" txt_i="1420" txt_f="1421">p</offsets></italic><offsets xml_i="6692" xml_f="7259" txt_i="1421" txt_f="1985"> &lt; 0.001; effect size = 0.65). TEAE frequency was 46.6% (61/131) with placebo and 67.4% (89/132) with SHP465 MAS; no serious TEAEs were reported. TEAEs reported at a frequency of ≥5% and ≥2 times the placebo rate were decreased appetite, insomnia, irritability, nausea, and decreased weight. Mean ± standard deviation increases (baseline to final on-treatment assessment) were higher with SHP465 MAS than placebo for pulse (5.7 ± 11.78 vs. 0.7 ± 10.79), systolic blood pressure (3.8 ± 9.15 vs. 2.1 ± 8.72), and diastolic blood pressure (4.0 ± 8.23 vs. 0.5 ± 7.45).</offsets></p><p><bold><italic><offsets xml_i="7280" xml_f="7292" txt_i="1986" txt_f="1998">Conclusions:</offsets></italic></bold><offsets xml_i="7308" xml_f="7613" txt_i="1998" txt_f="2303"> SHP465 MAS demonstrated superiority over placebo in improving ADHD symptoms and global functioning in children and adolescents with ADHD. The safety and tolerability profile of SHP465 MAS was consistent with that of SHP465 MAS in adults and other long-acting psychostimulants in children and adolescents.</offsets></p></abstract><kwd-group kwd-group-type="author"><title><bold>Keywords:</bold> </title><kwd>adolescents</kwd><kwd>attention-deficit/hyperactivity disorder</kwd><kwd>children</kwd><kwd>SHP465 mixed amphetamine salts</kwd></kwd-group><counts><fig-count count="2"></fig-count><table-count count="3"></table-count><ref-count count="21"></ref-count><page-count count="10"></page-count></counts></article-meta></front><body><sec sec-type="intro" id="s001"><title><offsets xml_i="8071" xml_f="8083" txt_i="2311" txt_f="2323">Introduction</offsets></title><p><offsets xml_i="8094" xml_f="8095" txt_i="2324" txt_f="2325">P</offsets><sc><offsets xml_i="8099" xml_f="8129" txt_i="2325" txt_f="2355">sychostimulants are considered</offsets></sc><offsets xml_i="8134" xml_f="8262" txt_i="2355" txt_f="2483"> first-line therapies for the treatment of attention-deficit/hyperactivity disorder (ADHD) in children and adolescents (Pliszka </offsets><xref rid="B14" ref-type="bibr"><offsets xml_i="8294" xml_f="8298" txt_i="2483" txt_f="2487">2007</offsets></xref><offsets xml_i="8305" xml_f="8327" txt_i="2487" txt_f="2509">; Atkinson and Hollis </offsets><xref rid="B1" ref-type="bibr"><offsets xml_i="8358" xml_f="8362" txt_i="2509" txt_f="2513">2010</offsets></xref><offsets xml_i="8369" xml_f="8514" txt_i="2513" txt_f="2658">). Multiple long-acting psychostimulant formulations are available for use in the treatment of children and adolescents with ADHD (Thomas et al. </offsets><xref rid="B21" ref-type="bibr"><offsets xml_i="8546" xml_f="8550" txt_i="2658" txt_f="2662">2013</offsets></xref><offsets xml_i="8557" xml_f="8575" txt_i="2662" txt_f="2680">; Briars and Todd </offsets><xref rid="B4" ref-type="bibr"><offsets xml_i="8606" xml_f="8610" txt_i="2680" txt_f="2684">2016</offsets></xref><offsets xml_i="8617" xml_f="8879" txt_i="2684" txt_f="2946">). However, prescribers sometimes supplement existing long-acting psychostimulants with an immediate-release psychostimulant later to potentially extend symptom coverage and maintain after-school activities in children and adolescents with ADHD (Briars and Todd </offsets><xref rid="B4" ref-type="bibr"><offsets xml_i="8910" xml_f="8914" txt_i="2946" txt_f="2950">2016</offsets></xref><offsets xml_i="8921" xml_f="9058" txt_i="2950" txt_f="3087">). Requiring individuals to take medication multiple times a day can lead to challenges in adherence in individuals with ADHD (Steinhoff </offsets><xref rid="B19" ref-type="bibr"><offsets xml_i="9090" xml_f="9094" txt_i="3087" txt_f="3091">2004</offsets></xref><offsets xml_i="9101" xml_f="9432" txt_i="3091" txt_f="3422">), suggesting that once-daily dosing is an important aspect of ADHD pharmacotherapy. In support of the importance of once-daily dosing, in a discrete choice experiment assessing preferred medication attributes, the number of administrations per day was reported as an important attribute in adolescents with ADHD (Glenngard et al. </offsets><xref rid="B10" ref-type="bibr"><offsets xml_i="9464" xml_f="9468" txt_i="3422" txt_f="3426">2013</offsets></xref><offsets xml_i="9475" xml_f="9477" txt_i="3426" txt_f="3428">).</offsets></p><p><offsets xml_i="9484" xml_f="10116" txt_i="3429" txt_f="4061">SHP465 mixed amphetamine salts (MAS) is a once-daily, extended-release, single-entity MAS product for oral administration approved for use in the United States for the treatment of ADHD in patients 13 years and older. SHP465 MAS contains equal amounts (by weight) of four salts: dextroamphetamine sulfate, amphetamine sulfate, dextroamphetamine saccharate, and amphetamine aspartate monohydrate. This results in a 3:1 mixture of dextro- to levoamphetamine base equivalent. SHP465 MAS capsules contain three types of drug-releasing beads, an immediate-release bead and two different types of delayed-release (DR) beads (Ermer et al. </offsets><xref rid="B7" ref-type="bibr"><offsets xml_i="10147" xml_f="10151" txt_i="4061" txt_f="4065">2007</offsets></xref><offsets xml_i="10158" xml_f="10263" txt_i="4065" txt_f="4170">). The first DR bead releases amphetamine at pH 5.5 and the other DR bead releases amphetamine at pH 7.0.</offsets></p><p><offsets xml_i="10270" xml_f="10612" txt_i="4171" txt_f="4513">The short-term efficacy, safety, and tolerability of SHP465 MAS in adults with ADHD have been investigated in several phase 3 clinical trials. In a 7-week study, dose-optimized SHP465 MAS (12.5–75 mg) exhibited superiority over placebo in reducing ADHD Rating Scale IV (ADHD-RS-IV) total score (the primary efficacy endpoint) (Spencer et al. </offsets><xref rid="B17" ref-type="bibr"><offsets xml_i="10644" xml_f="10648" txt_i="4513" txt_f="4517">2008</offsets></xref><offsets xml_i="10655" xml_f="10819" txt_i="4517" txt_f="4681">). In a 6-week study, forced-dose SHP465 MAS (25, 50, or 75 mg) also produced significantly greater reductions in ADHD-RS-IV total score than placebo (Frick et al. </offsets><xref rid="B9" ref-type="bibr"><offsets xml_i="10850" xml_f="10854" txt_i="4681" txt_f="4685">2017</offsets></xref><offsets xml_i="10861" xml_f="11105" txt_i="4685" txt_f="4929">). Across these short-term phase 3 clinical studies, treatment-emergent adverse events (TEAEs) that occurred in ≥10% of participants taking SHP465 MAS were insomnia, dry mouth, decreased appetite, headache, and decreased weight (Spencer et al. </offsets><xref rid="B17" ref-type="bibr"><offsets xml_i="11137" xml_f="11141" txt_i="4929" txt_f="4933">2008</offsets></xref><offsets xml_i="11148" xml_f="11163" txt_i="4933" txt_f="4948">; Frick et al. </offsets><xref rid="B9" ref-type="bibr"><offsets xml_i="11194" xml_f="11198" txt_i="4948" txt_f="4952">2017</offsets></xref><offsets xml_i="11205" xml_f="11207" txt_i="4952" txt_f="4954">).</offsets></p><p><offsets xml_i="11214" xml_f="11682" txt_i="4955" txt_f="5423">To date, there are no published phase 3 clinical studies on the efficacy, safety, and tolerability of SHP465 MAS in children (aged 6–12 years) and adolescents (aged 13–17 years) with ADHD. As such, this report is the first to describe a phase 3 clinical study of SHP465 MAS in children and adolescents with ADHD. The objectives were to evaluate the efficacy, safety, and tolerability of SHP465 MAS versus placebo in the treatment of children and adolescents with ADHD.</offsets></p></sec><sec sec-type="methods" id="s002"><title><offsets xml_i="11733" xml_f="11740" txt_i="5425" txt_f="5432">Methods</offsets></title><sec id="s003"><title><offsets xml_i="11770" xml_f="11796" txt_i="5433" txt_f="5459">Study design and treatment</offsets></title><p><offsets xml_i="11807" xml_f="11901" txt_i="5460" txt_f="5554">This was a randomized, multicenter, double-blind, placebo-controlled dose-optimization study (</offsets><uri xlink:type="simple" xlink:href="http://ClinicalTrials.gov"><offsets xml_i="11965" xml_f="11983" txt_i="5554" txt_f="5572">ClinicalTrials.gov</offsets></uri><offsets xml_i="11989" xml_f="12767" txt_i="5572" txt_f="6350">: NCT02466425). The study was conducted at 36 sites in the United States between June 18, 2015, and February 16, 2016. The study protocol, protocol amendments, final informed consent document, and relevant supporting information were submitted to and approved by an Institutional Review Board and regulatory agency before study initiation. This study was conducted in accordance with the International Conference on Harmonisation of Good Clinical Practice, principles of the Declaration of Helsinki, and local ethical and legal requirements. Written informed consent was obtained before conducting any study-specific procedures; consent and assent were documented by the dated signature of the participant and the participant's parent(s) or legally authorized representative(s).</offsets></p><p><offsets xml_i="12774" xml_f="13445" txt_i="6351" txt_f="7022">The study consisted of four periods: a screening and washout period, a dose-optimization period of 2 weeks, a dose-maintenance period of 2 weeks, and a safety follow-up period. Participants were randomized 1:1 to placebo or dose-optimized SHP465 MAS (12.5 or 25 mg) after the screening and washout period, which allowed for carryover effects of previous medications to abate. Randomization was stratified by age group (children vs. adolescents) to facilitate balance of treatment allocation. Treatment allocation was automatically assigned using interactive response technology; to protect study blinding, placebo capsules were indistinguishable from SHP465 MAS capsules.</offsets></p><p><offsets xml_i="13452" xml_f="14366" txt_i="7023" txt_f="7937">The doses chosen for use in this study were determined based primarily on results from an unpublished phase 2 study in adolescents with ADHD. This study evaluated the safety and duration of effect of SHP465 MAS and demonstrated that 25 mg SHP465 MAS in adolescents with ADHD provided the target duration of effect and exhibited an overall safety and tolerability profile that was similar to that seen in other studies of MAS. Although no clinical data were available on the use of SHP465 MAS in children aged 6–12 years at the time the study was designed, it was speculated that the potential benefit–risk ratio of SHP465 MAS in children was similar to that of adolescents. Given the tolerability and efficacy of 25 mg SHP465 MAS in adolescents with ADHD and the relatively lower body weight of children compared with adolescents, 12.5 mg SHP465 MAS was selected as an initial dose in this dose-optimization study.</offsets></p><p><offsets xml_i="14373" xml_f="15431" txt_i="7938" txt_f="8996">During dose optimization, all participants randomized to SHP465 MAS initiated treatment at a dose of 12.5 mg. Participants were titrated to 25 mg SHP465 MAS by the investigator, based on symptom response and tolerability, at the week 1 visit. The investigator categorized participant response into one of three conditions (intolerable response, ineffective response, and acceptable response), with acceptable response defined as the participant having achieved ≥30% ADHD-RS-IV total score reduction from baseline, having a Clinical Global Impressions-Improvement (CGI-I) score of 1 (very much improved) or 2 (much improved), and the dose being well tolerated. A single dose reduction was permitted during the dose-optimization period, with the last dose change allowed at the week 2 visit; those unable to tolerate SHP465 MAS were discontinued. During dose maintenance, participants were maintained on the optimized dose of SHP465 MAS established during the dose-optimization period. Throughout the study, study medication was to be taken at 7 AM (±2 hours).</offsets></p></sec><sec id="s004"><title><offsets xml_i="15463" xml_f="15475" txt_i="8998" txt_f="9010">Participants</offsets></title><p><offsets xml_i="15486" xml_f="15608" txt_i="9011" txt_f="9133">Males or nonpregnant nonlactating females (aged 6–17 years at the time of consent) with a primary ADHD diagnosis based on </offsets><italic><offsets xml_i="15616" xml_f="15712" txt_i="9133" txt_f="9229">Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR)</offsets></italic><offsets xml_i="15721" xml_f="16210" txt_i="9229" txt_f="9718"> criteria and baseline ADHD-RS-IV total scores ≥28 were eligible to participate. Participants were also required to have a satisfactory medical assessment with no clinically significant or relevant abnormalities and to be functioning at an age-appropriate intellectual level. Individuals were also required to be untreated or not to be completely satisfied with their current ADHD medication; those who were satisfied with their current treatment were not eligible for study participation.</offsets></p><p><offsets xml_i="16217" xml_f="17582" txt_i="9719" txt_f="11078">Key exclusion criteria included having a comorbid psychiatric diagnosis with significant symptoms/symptomatic manifestations that could contraindicate treatment or confound efficacy or safety assessments or a concurrent condition that could confound safety assessments or increase participant risk; a history of a chronic tic disorder, a current tic disorder, a history of tics that were judged by the investigator to be exclusionary, or a diagnosis of Tourette's syndrome; being considered a suicide risk, or having had a previous suicide attempt, or demonstrating active suicidal ideation; being underweight (body mass index [BMI] &lt;3rd percentile) or overweight (BMI &gt;97th percentile) at screening based on the Centers for Disease Control and Prevention's age- and sex-specific values; having blood pressure exceeding the 90th percentile for age, sex, and height at screening and baseline; having hypertension; having symptomatic cardiovascular disease, cardiac issues, a clinically significant electrocardiogram (ECG), or a family history of sudden cardiac death or ventricular arrhythmia; having a documented allergy, hypersensitivity, or intolerance to amphetamine or excipients in SHP465 MAS; having failed to respond to a previous course of amphetamine therapy; having a history of suspected substance abuse or dependence (excluding nicotine) based on </offsets><italic><offsets xml_i="17590" xml_f="17599" txt_i="11078" txt_f="11087">DSM-IV-TR</offsets></italic><offsets xml_i="17608" xml_f="17712" txt_i="11087" txt_f="11191"> criteria; or taking a prohibited medication that was excluded or had not been appropriately washed out.</offsets></p></sec><sec id="s005"><title><offsets xml_i="17744" xml_f="17762" txt_i="11193" txt_f="11211">Efficacy endpoints</offsets></title><p><offsets xml_i="17773" xml_f="18072" txt_i="11212" txt_f="11511">Efficacy assessments were completed by clinicians experienced in the evaluation of ADHD in children and adolescents. The primary efficacy endpoint was change in ADHD-RS-IV total score from baseline to week 4. The ADHD-RS-IV was developed to assess ADHD symptoms in children and adolescents based on </offsets><italic><offsets xml_i="18080" xml_f="18089" txt_i="11511" txt_f="11520">DSM-IV-TR</offsets></italic><offsets xml_i="18098" xml_f="18123" txt_i="11520" txt_f="11545"> criteria (Dupaul et al. </offsets><xref rid="B6" ref-type="bibr"><offsets xml_i="18154" xml_f="18158" txt_i="11545" txt_f="11549">1998</offsets></xref><offsets xml_i="18165" xml_f="18682" txt_i="11549" txt_f="12066">). It consists of 18 items designed to reflect current ADHD symptoms, with items scored on 4-point scales (0 [no symptoms] to 3 [severe symptoms]). Total scores range from 0 to 54, with higher scores indicating more severe symptoms. Subscale scores can also be calculated by summing responses to the even-numbered items (hyperactivity/impulsivity subscale) or odd-numbered items (inattentiveness subscale). The ADHD-RS-IV was administered at baseline and all postbaseline visits through week 4/early termination (ET).</offsets></p><p><offsets xml_i="18689" xml_f="18908" txt_i="12067" txt_f="12286">The key secondary endpoint was the score on the CGI-I scale at week 4. The CGI-I measures global functioning improvement on a 7-point scale (1 [very much improved] to 7 [very much worse]; 0 indicates not assessed) (Guy </offsets><xref rid="B11" ref-type="bibr"><offsets xml_i="18940" xml_f="18944" txt_i="12286" txt_f="12290">1976</offsets></xref><offsets xml_i="18951" xml_f="19243" txt_i="12290" txt_f="12582">), with improvement measured against baseline CGI-Severity (CGI-S) scores. Other secondary efficacy assessments included ADHD-RS-IV hyperactivity/impulsivity and inattentiveness subscale score changes from baseline to week 4 and global functioning improvement based on the dichotomized CGI-I.</offsets></p></sec><sec id="s006"><title><offsets xml_i="19275" xml_f="19308" txt_i="12584" txt_f="12617">Safety and tolerability endpoints</offsets></title><p><offsets xml_i="19319" xml_f="19714" txt_i="12618" txt_f="13013">Adverse events (AEs) were collected from the time of informed consent and at every study visit until the defined follow-up period. TEAEs were defined as AEs that started after the first study drug dose or that started before the first study drug dose, but increased in severity after the first study drug dose. TEAEs were categorized based on severity, relatedness to treatment, and seriousness.</offsets></p><p><offsets xml_i="19721" xml_f="20104" txt_i="13014" txt_f="13397">Vital signs and weight were assessed at all visits. Vital signs were measured after ∼3 minutes of rest while the participant was seated and consisted of three assessments taken at ∼2-minute intervals. The 12-lead ECG was assessed at screening, baseline, week 2, and week 4/ET after 3 minutes of rest; the baseline assessment consisted of three recordings taken at 3-minute intervals.</offsets></p><p><offsets xml_i="20111" xml_f="20178" txt_i="13398" txt_f="13465">The Columbia-Suicide Severity Rating Scale (C-SSRS) (Posner et al. </offsets><xref rid="B15" ref-type="bibr"><offsets xml_i="20210" xml_f="20214" txt_i="13465" txt_f="13469">2011</offsets></xref><offsets xml_i="20221" xml_f="20476" txt_i="13469" txt_f="13724">) was used at baseline and each study visit by an individual who was medically responsible for the participant. The C-SSRS is a semistructured interview designed to capture the occurrence, severity, and frequency of suicide-related thoughts and behaviors.</offsets></p></sec><sec id="s007"><title><offsets xml_i="20508" xml_f="20550" txt_i="13726" txt_f="13768">Data presentation and statistical analyses</offsets></title><p><offsets xml_i="20561" xml_f="20893" txt_i="13769" txt_f="14101">Sample size was determined using nQuery Advisor 7.0 (Statistical Solutions, Ltd., Cork, Ireland). To detect an assumed treatment difference (SHP465 MAS–placebo) of 6.0, with an assumed common standard deviation (SD) of 10.0 for ADHD-RS-IV total score change, 60 participants/group were required to provide 90% power for a two-sided </offsets><italic><offsets xml_i="20901" xml_f="20902" txt_i="14101" txt_f="14102">t</offsets></italic><offsets xml_i="20911" xml_f="21765" txt_i="14102" txt_f="14956">-test (α = 0.05). Taking into account an expected 20% postrandomization dropout rate, at least 150 participants needed to be randomized. A blinded interim sample size reestimation was performed when ∼75% of randomized participants had either completed or discontinued from the study, among which 118 were in the full analysis set (FAS; randomized participants taking ≥1 study drug dose and having ≥1 postdose primary efficacy assessment) and 107 had completed the study. Based on the pooled SD of 13.66, the recalculated sample size was 110 participants/group (220 in total) without changing the original statistical assumptions (90% power; treatment difference of 6.0; two-sided significance level of 0.05). Taking into account an expected 20% postrandomization dropout rate for those not in the interim cohort, the overall randomization target was 264.</offsets></p><p><offsets xml_i="21772" xml_f="22481" txt_i="14957" txt_f="15666">Efficacy analyses were performed in the FAS; all statistical tests were two-sided and performed at the 0.05 level of significance. The primary efficacy endpoint, change in ADHD-RS-IV total score from baseline to week 4, was analyzed using the linear mixed-effects model for repeated measures (MMRM) with treatment, visit, age group (6–12 years vs. 13–17 years), and the interaction of treatment × visit as factors; baseline ADHD-RS-IV total score as a covariate; and the interaction of baseline ADHD-RS-IV total score × visit adjusted in the model. Treatment comparisons were based on least squares (LS) mean treatment differences (SHP465 MAS–placebo), with the corresponding 95% confidence interval (CI) and </offsets><italic><offsets xml_i="22489" xml_f="22490" txt_i="15666" txt_f="15667">p</offsets></italic><offsets xml_i="22499" xml_f="22863" txt_i="15667" txt_f="16031">-value; effect size was also determined. Two sensitivity analyses (placebo multiple imputation and multiple imputations with penalties applied to dropouts) were used to examine the robustness of the primary MMRM analysis. Change from baseline at week 4 on the ADHD-RS-IV subscales was also analyzed using the MMRM model described for the primary efficacy endpoint.</offsets></p><p><offsets xml_i="22870" xml_f="23626" txt_i="16032" txt_f="16788">Assessment of the key secondary efficacy endpoint, CGI-I score at week 4, was assessed using the MMRM method described for the primary efficacy analysis. The analysis accounted for baseline CGI-S as a covariate and adjusted for the interaction of baseline CGI-S × visit. A supportive analysis of the CGI-I was based on dichotomized improvement (improved vs. not improved) at the final on-treatment assessment. Participants were categorized as improved if the CGI-I score was 1 (very much improved) or 2 (much improved) and as not improved if the CGI-I score was 3 (minimally improved) through 7 (very much worse). Statistical assessment of the dichotomized CGI-I consisted of a Cochran-Mantel-Haenszel (CMH) test stratified by age group and baseline CGI-S.</offsets></p><p><offsets xml_i="23633" xml_f="24174" txt_i="16789" txt_f="17330">To preserve study-wide type I error (two-sided α = 0.05) across the primary and key secondary efficacy endpoints, a fixed-sequence test procedure was applied. For this procedure, hypotheses were tested in order (first the primary endpoint and then the secondary endpoint). The secondary endpoint could only attain significance if the primary endpoint was significant at the two-sided 0.05 significance level. For analyses not included in the fixed-sequence test procedure (dichotomized CGI-I and ADHD-RS-IV subscale score changes), reported </offsets><italic><offsets xml_i="24182" xml_f="24183" txt_i="17330" txt_f="17331">p</offsets></italic><offsets xml_i="24192" xml_f="24272" txt_i="17331" txt_f="17411">-values are nominal (unadjusted) and are reported for descriptive purposes only.</offsets></p><p><offsets xml_i="24279" xml_f="24699" txt_i="17412" txt_f="17832">Safety and tolerability were analyzed in the safety analysis set (randomized participants taking ≥1 study drug dose). All safety and tolerability data are presented using descriptive statistics. For each endpoint, baseline was assessed as the last value collected before the first dose of the double-blind study drug and the final on-treatment assessment was defined as the last valid assessment obtained after baseline.</offsets></p></sec></sec><sec sec-type="results" id="s008"><title><offsets xml_i="24756" xml_f="24763" txt_i="17835" txt_f="17842">Results</offsets></title><sec id="s009"><title><offsets xml_i="24793" xml_f="24833" txt_i="17843" txt_f="17883">Participant disposition and demographics</offsets></title><p><offsets xml_i="24844" xml_f="24885" txt_i="17884" txt_f="17925">Participant disposition is summarized in </offsets><xref ref-type="fig" rid="f1"><offsets xml_i="24915" xml_f="24923" txt_i="17925" txt_f="17933">Figure 1</offsets></xref><offsets xml_i="24930" xml_f="24992" txt_i="17933" txt_f="17995">. Of 338 screened participants, 264 were randomized (placebo, </offsets><italic><offsets xml_i="25000" xml_f="25001" txt_i="17995" txt_f="17996">n</offsets></italic><offsets xml_i="25010" xml_f="25030" txt_i="17996" txt_f="18016"> = 132; SHP465 MAS, </offsets><italic><offsets xml_i="25038" xml_f="25039" txt_i="18016" txt_f="18017">n</offsets></italic><offsets xml_i="25048" xml_f="25101" txt_i="18017" txt_f="18070"> = 132). During the study, 29 participants (placebo, </offsets><italic><offsets xml_i="25109" xml_f="25110" txt_i="18070" txt_f="18071">n</offsets></italic><offsets xml_i="25119" xml_f="25138" txt_i="18071" txt_f="18090"> = 13; SHP465 MAS, </offsets><italic><offsets xml_i="25146" xml_f="25147" txt_i="18090" txt_f="18091">n</offsets></italic><offsets xml_i="25156" xml_f="25278" txt_i="18091" txt_f="18213"> = 16) discontinued from the study. The most frequent reason for study discontinuation was lack of efficacy with placebo (</offsets><italic><offsets xml_i="25286" xml_f="25287" txt_i="18213" txt_f="18214">n</offsets></italic><offsets xml_i="25296" xml_f="25329" txt_i="18214" txt_f="18247"> = 4) and TEAEs with SHP465 MAS (</offsets><italic><offsets xml_i="25337" xml_f="25338" txt_i="18247" txt_f="18248">n</offsets></italic><offsets xml_i="25347" xml_f="25374" txt_i="18248" txt_f="18275"> = 11; see footnote “†” of </offsets><xref ref-type="table" rid="T2"><offsets xml_i="25406" xml_f="25413" txt_i="18275" txt_f="18282">Table 2</offsets></xref><offsets xml_i="25420" xml_f="25598" txt_i="18282" txt_f="18460"> for a complete list of TEAEs leading to study discontinuation). Additional reasons for study discontinuation in ≥2 participants in either treatment group included AEs (placebo, </offsets><italic><offsets xml_i="25606" xml_f="25607" txt_i="18460" txt_f="18461">n</offsets></italic><offsets xml_i="25616" xml_f="25651" txt_i="18461" txt_f="18496"> = 3), lost to follow-up (placebo, </offsets><italic><offsets xml_i="25659" xml_f="25660" txt_i="18496" txt_f="18497">n</offsets></italic><offsets xml_i="25669" xml_f="25715" txt_i="18497" txt_f="18543"> = 2), withdrawn by parent/guardian (placebo, </offsets><italic><offsets xml_i="25723" xml_f="25724" txt_i="18543" txt_f="18544">n</offsets></italic><offsets xml_i="25733" xml_f="25763" txt_i="18544" txt_f="18574"> = 2), and other (SHP465 MAS, </offsets><italic><offsets xml_i="25771" xml_f="25772" txt_i="18574" txt_f="18575">n</offsets></italic><offsets xml_i="25781" xml_f="25787" txt_i="18575" txt_f="18581"> = 3).</offsets></p><fig id="f1" fig-type="figure" orientation="portrait" position="float"><label><bold><offsets xml_i="25875" xml_f="25882" txt_i="18582" txt_f="18589">FIG. 1.</offsets></bold></label><caption><p><offsets xml_i="25909" xml_f="25987" txt_i="18589" txt_f="18667">Participant disposition. FAS, full analysis set; MAS, mixed amphetamine salts.</offsets></p></caption><graphic xlink:href="fig-1"></graphic></fig><p><offsets xml_i="26048" xml_f="26135" txt_i="18668" txt_f="18755">Demographic and baseline clinical characteristics by treatment group are summarized in </offsets><xref ref-type="table" rid="T1"><offsets xml_i="26167" xml_f="26174" txt_i="18755" txt_f="18762">Table 1</offsets></xref><offsets xml_i="26181" xml_f="26478" txt_i="18762" txt_f="19059">. Most participants were males (163/263 [62.0%]) and white (161/263 [61.2%]); mean ± SD age was 12.5 ± 3.24 years. In the overall study population, mean ± SD time since ADHD diagnosis was 5.0 ± 4.02 years, and most participants (199/263 [75.7%]) were diagnosed as having the combined ADHD subtype.</offsets></p><table-wrap id="T1" orientation="portrait" position="float"><label><sc><offsets xml_i="26553" xml_f="26558" txt_i="19060" txt_f="19065">Table</offsets></sc><offsets xml_i="26563" xml_f="26566" txt_i="19065" txt_f="19068"> 1.</offsets></label><caption><p><sc><offsets xml_i="26590" xml_f="26664" txt_i="19068" txt_f="19142">Participant Demographics and Clinical Characteristics, Safety Analysis Set</offsets></sc></p></caption><table frame="hsides" rules="groups"><colgroup><col align="left"></col><col align="left"></col><col align="left"></col></colgroup><thead><tr><th align="left"><offsets xml_i="26841" xml_f="26842" txt_i="19143" txt_f="19144"> </offsets></th><th align="center"><italic><offsets xml_i="26874" xml_f="26883" txt_i="19144" txt_f="19153">Placebo (</offsets></italic><offsets xml_i="26892" xml_f="26893" txt_i="19153" txt_f="19154">n</offsets><italic><offsets xml_i="26901" xml_f="26908" txt_i="19154" txt_f="19161"> = 131)</offsets></italic></th><th align="center"><italic><offsets xml_i="26949" xml_f="26961" txt_i="19161" txt_f="19173">SHP465 MAS (</offsets></italic><offsets xml_i="26970" xml_f="26971" txt_i="19173" txt_f="19174">n</offsets><italic><offsets xml_i="26979" xml_f="26986" txt_i="19174" txt_f="19181"> = 132)</offsets></italic></th></tr></thead><tbody><tr><td align="left"><offsets xml_i="27041" xml_f="27061" txt_i="19181" txt_f="19201">Mean ± SD age, years</offsets></td><td align="center"><offsets xml_i="27085" xml_f="27096" txt_i="19202" txt_f="19213">12.5 ± 3.24</offsets></td><td align="center"><offsets xml_i="27120" xml_f="27131" txt_i="19214" txt_f="19225">12.4 ± 3.25</offsets></td></tr><tr><td colspan="3" align="left"><offsets xml_i="27174" xml_f="27188" txt_i="19226" txt_f="19240">Age category, </offsets><italic><offsets xml_i="27196" xml_f="27197" txt_i="19240" txt_f="19241">n</offsets></italic><offsets xml_i="27206" xml_f="27210" txt_i="19241" txt_f="19245"> (%)</offsets></td></tr><tr><td align="left"><offsets xml_i="27241" xml_f="27252" txt_i="19246" txt_f="19257"> 6–12 years</offsets></td><td align="center"><offsets xml_i="27276" xml_f="27285" txt_i="19258" txt_f="19267">52 (39.7)</offsets></td><td align="center"><offsets xml_i="27309" xml_f="27318" txt_i="19268" txt_f="19277">54 (40.9)</offsets></td></tr><tr><td align="left"><offsets xml_i="27349" xml_f="27361" txt_i="19278" txt_f="19290"> 13–17 years</offsets></td><td align="center"><offsets xml_i="27385" xml_f="27394" txt_i="19291" txt_f="19300">79 (60.3)</offsets></td><td align="center"><offsets xml_i="27418" xml_f="27427" txt_i="19301" txt_f="19310">78 (59.1)</offsets></td></tr><tr><td colspan="3" align="left"><offsets xml_i="27470" xml_f="27478" txt_i="19311" txt_f="19319">Gender, </offsets><italic><offsets xml_i="27486" xml_f="27487" txt_i="19319" txt_f="19320">n</offsets></italic><offsets xml_i="27496" xml_f="27500" txt_i="19320" txt_f="19324"> (%)</offsets></td></tr><tr><td align="left"><offsets xml_i="27531" xml_f="27536" txt_i="19325" txt_f="19330"> Male</offsets></td><td align="center"><offsets xml_i="27560" xml_f="27569" txt_i="19331" txt_f="19340">77 (58.8)</offsets></td><td align="center"><offsets xml_i="27593" xml_f="27602" txt_i="19341" txt_f="19350">86 (65.2)</offsets></td></tr><tr><td colspan="3" align="left"><offsets xml_i="27645" xml_f="27651" txt_i="19351" txt_f="19357">Race, </offsets><italic><offsets xml_i="27659" xml_f="27660" txt_i="19357" txt_f="19358">n</offsets></italic><offsets xml_i="27669" xml_f="27673" txt_i="19358" txt_f="19362"> (%)</offsets></td></tr><tr><td align="left"><offsets xml_i="27704" xml_f="27710" txt_i="19363" txt_f="19369"> White</offsets></td><td align="center"><offsets xml_i="27734" xml_f="27743" txt_i="19370" txt_f="19379">83 (63.4)</offsets></td><td align="center"><offsets xml_i="27767" xml_f="27776" txt_i="19380" txt_f="19389">78 (59.1)</offsets></td></tr><tr><td align="left"><offsets xml_i="27807" xml_f="27813" txt_i="19390" txt_f="19396"> Black</offsets></td><td align="center"><offsets xml_i="27837" xml_f="27846" txt_i="19397" txt_f="19406">37 (28.2)</offsets></td><td align="center"><offsets xml_i="27870" xml_f="27879" txt_i="19407" txt_f="19416">38 (28.8)</offsets></td></tr><tr><td align="left"><offsets xml_i="27910" xml_f="27916" txt_i="19417" txt_f="19423"> Asian</offsets></td><td align="center"><offsets xml_i="27940" xml_f="27941" txt_i="19424" txt_f="19425">0</offsets></td><td align="center"><offsets xml_i="27965" xml_f="27972" txt_i="19426" txt_f="19433">1 (0.8)</offsets></td></tr><tr><td align="left"><offsets xml_i="28003" xml_f="28012" txt_i="19434" txt_f="19443"> Multiple</offsets></td><td align="center"><offsets xml_i="28036" xml_f="28043" txt_i="19444" txt_f="19451">9 (6.9)</offsets></td><td align="center"><offsets xml_i="28067" xml_f="28075" txt_i="19452" txt_f="19460">12 (9.1)</offsets></td></tr><tr><td align="left"><offsets xml_i="28106" xml_f="28112" txt_i="19461" txt_f="19467"> Other</offsets></td><td align="center"><offsets xml_i="28136" xml_f="28143" txt_i="19468" txt_f="19475">2 (1.5)</offsets></td><td align="center"><offsets xml_i="28167" xml_f="28174" txt_i="19476" txt_f="19483">3 (2.3)</offsets></td></tr><tr><td align="left"><offsets xml_i="28205" xml_f="28225" txt_i="19484" txt_f="19504">Mean ± SD weight, kg</offsets></td><td align="center"><offsets xml_i="28249" xml_f="28263" txt_i="19505" txt_f="19519">51.92 ± 18.255</offsets></td><td align="center"><offsets xml_i="28287" xml_f="28301" txt_i="19520" txt_f="19534">51.30 ± 17.560</offsets></td></tr><tr><td align="left"><offsets xml_i="28332" xml_f="28351" txt_i="19535" txt_f="19554">Mean ± SD BMI, kg/m</offsets><sup><offsets xml_i="28356" xml_f="28357" txt_i="19554" txt_f="19555">2</offsets></sup></td><td align="center"><offsets xml_i="28387" xml_f="28400" txt_i="19556" txt_f="19569">20.98 ± 4.143</offsets></td><td align="center"><offsets xml_i="28424" xml_f="28437" txt_i="19570" txt_f="19583">20.45 ± 3.784</offsets></td></tr><tr><td align="left"><offsets xml_i="28468" xml_f="28510" txt_i="19584" txt_f="19626">Mean ± SD time since ADHD diagnosis, years</offsets></td><td align="center"><offsets xml_i="28534" xml_f="28544" txt_i="19627" txt_f="19637">4.9 ± 3.94</offsets></td><td align="center"><offsets xml_i="28568" xml_f="28578" txt_i="19638" txt_f="19648">5.1 ± 4.11</offsets></td></tr><tr><td colspan="3" align="left"><offsets xml_i="28621" xml_f="28635" txt_i="19649" txt_f="19663">ADHD subtype, </offsets><italic><offsets xml_i="28643" xml_f="28644" txt_i="19663" txt_f="19664">n</offsets></italic><offsets xml_i="28653" xml_f="28657" txt_i="19664" txt_f="19668"> (%)</offsets></td></tr><tr><td align="left"><offsets xml_i="28688" xml_f="28700" txt_i="19669" txt_f="19681"> Inattentive</offsets></td><td align="center"><offsets xml_i="28724" xml_f="28733" txt_i="19682" txt_f="19691">29 (22.1)</offsets></td><td align="center"><offsets xml_i="28757" xml_f="28766" txt_i="19692" txt_f="19701">32 (24.2)</offsets></td></tr><tr><td align="left"><offsets xml_i="28797" xml_f="28819" txt_i="19702" txt_f="19724"> Hyperactive/impulsive</offsets></td><td align="center"><offsets xml_i="28843" xml_f="28850" txt_i="19725" txt_f="19732">1 (0.8)</offsets></td><td align="center"><offsets xml_i="28874" xml_f="28881" txt_i="19733" txt_f="19740">2 (1.5)</offsets></td></tr><tr><td align="left"><offsets xml_i="28912" xml_f="28921" txt_i="19741" txt_f="19750"> Combined</offsets></td><td align="center"><offsets xml_i="28945" xml_f="28955" txt_i="19751" txt_f="19761">101 (77.1)</offsets></td><td align="center"><offsets xml_i="28979" xml_f="28988" txt_i="19762" txt_f="19771">98 (74.2)</offsets></td></tr><tr><td colspan="3" align="left"><offsets xml_i="29031" xml_f="29057" txt_i="19772" txt_f="19798">Mean ± SD ADHD-RS-IV score</offsets></td></tr><tr><td align="left"><offsets xml_i="29088" xml_f="29094" txt_i="19799" txt_f="19805"> Total</offsets></td><td align="center"><offsets xml_i="29118" xml_f="29129" txt_i="19806" txt_f="19817">40.1 ± 7.01</offsets></td><td align="center"><offsets xml_i="29153" xml_f="29164" txt_i="19818" txt_f="19829">39.0 ± 7.02</offsets></td></tr><tr><td align="left"><offsets xml_i="29195" xml_f="29221" txt_i="19830" txt_f="19856"> Hyperactivity/impulsivity</offsets><sup><xref ref-type="table-fn" rid="tf1"><offsets xml_i="29262" xml_f="29263" txt_i="19856" txt_f="19857">*</offsets></xref></sup></td><td align="center"><offsets xml_i="29300" xml_f="29311" txt_i="19858" txt_f="19869">17.9 ± 5.52</offsets></td><td align="center"><offsets xml_i="29335" xml_f="29346" txt_i="19870" txt_f="19881">17.0 ± 5.86</offsets></td></tr><tr><td align="left"><offsets xml_i="29377" xml_f="29393" txt_i="19882" txt_f="19898"> Inattentiveness</offsets><sup><xref ref-type="table-fn" rid="tf1"><offsets xml_i="29434" xml_f="29435" txt_i="19898" txt_f="19899">*</offsets></xref></sup></td><td align="center"><offsets xml_i="29472" xml_f="29483" txt_i="19900" txt_f="19911">22.1 ± 3.57</offsets></td><td align="center"><offsets xml_i="29507" xml_f="29518" txt_i="19912" txt_f="19923">22.0 ± 3.20</offsets></td></tr><tr><td colspan="3" align="left"><offsets xml_i="29561" xml_f="29576" txt_i="19924" txt_f="19939">CGI-S category,</offsets><sup><xref ref-type="table-fn" rid="tf2"><offsets xml_i="29617" xml_f="29618" txt_i="19939" txt_f="19940">†</offsets></xref></sup><italic><offsets xml_i="29639" xml_f="29640" txt_i="19940" txt_f="19941">n</offsets></italic><offsets xml_i="29649" xml_f="29653" txt_i="19941" txt_f="19945"> (%)</offsets></td></tr><tr><td align="left"><offsets xml_i="29684" xml_f="29695" txt_i="19946" txt_f="19957"> Mildly ill</offsets></td><td align="center"><offsets xml_i="29719" xml_f="29720" txt_i="19958" txt_f="19959">0</offsets></td><td align="center"><offsets xml_i="29744" xml_f="29751" txt_i="19960" txt_f="19967">3 (2.3)</offsets></td></tr><tr><td align="left"><offsets xml_i="29782" xml_f="29797" txt_i="19968" txt_f="19983"> Moderately ill</offsets></td><td align="center"><offsets xml_i="29821" xml_f="29830" txt_i="19984" txt_f="19993">55 (42.0)</offsets></td><td align="center"><offsets xml_i="29854" xml_f="29863" txt_i="19994" txt_f="20003">53 (40.2)</offsets></td></tr><tr><td align="left"><offsets xml_i="29894" xml_f="29907" txt_i="20004" txt_f="20017"> Markedly ill</offsets></td><td align="center"><offsets xml_i="29931" xml_f="29940" txt_i="20018" txt_f="20027">64 (48.9)</offsets></td><td align="center"><offsets xml_i="29964" xml_f="29973" txt_i="20028" txt_f="20037">65 (49.2)</offsets></td></tr><tr><td align="left"><offsets xml_i="30004" xml_f="30017" txt_i="20038" txt_f="20051"> Severely ill</offsets></td><td align="center"><offsets xml_i="30041" xml_f="30049" txt_i="20052" txt_f="20060">12 (9.2)</offsets></td><td align="center"><offsets xml_i="30073" xml_f="30081" txt_i="20061" txt_f="20069">11 (8.3)</offsets></td></tr></tbody></table><table-wrap-foot><fn id="tf1"><label><sup><offsets xml_i="30149" xml_f="30150" txt_i="20070" txt_f="20071">*</offsets></sup></label><p><offsets xml_i="30167" xml_f="30195" txt_i="20071" txt_f="20099">Based on full analysis set (</offsets><italic><offsets xml_i="30203" xml_f="30204" txt_i="20099" txt_f="20100">n</offsets></italic><offsets xml_i="30213" xml_f="30233" txt_i="20100" txt_f="20120"> = 129 for placebo; </offsets><italic><offsets xml_i="30241" xml_f="30242" txt_i="20120" txt_f="20121">n</offsets></italic><offsets xml_i="30251" xml_f="30274" txt_i="20121" txt_f="20144"> = 128 for SHP465 MAS).</offsets></p></fn><fn id="tf2"><label><sup><offsets xml_i="30308" xml_f="30309" txt_i="20145" txt_f="20146">†</offsets></sup></label><p><offsets xml_i="30326" xml_f="30444" txt_i="20146" txt_f="20264">No participants were categorized as normal (not at all ill), borderline mentally ill, or among the most extremely ill.</offsets></p></fn><fn id="tf3"><p><offsets xml_i="30469" xml_f="30671" txt_i="20265" txt_f="20467">ADHD, attention-deficit/hyperactivity disorder; ADHD-RS-IV, ADHD Rating Scale IV; BMI, body mass index; CGI-S, Clinical Global Impressions-Severity; MAS, mixed amphetamine salts; SD, standard deviation.</offsets></p></fn></table-wrap-foot></table-wrap></sec><sec id="s010"><title></title><p><offsets xml_i="30750" xml_f="31008" txt_i="20470" txt_f="20728">Prior ADHD medication use was reported by 74.0% (97/131) of the placebo group and 79.5% (105/132) of the SHP465 MAS group. The ADHD medications used most frequently before entering the study were methylphenidate, lisdexamfetamine, and immediate-release MAS (</offsets><xref ref-type="supplementary-material" rid="SD1"><offsets xml_i="31058" xml_f="31080" txt_i="20728" txt_f="20750">Supplementary Table S1</offsets></xref><offsets xml_i="31087" xml_f="31132" txt_i="20750" txt_f="20795">; Supplementary Data are available online at </offsets><uri xlink:type="simple" xlink:href="http://www.liebertpub.com/cap"><offsets xml_i="31200" xml_f="31222" txt_i="20795" txt_f="20817">www.liebertpub.com/cap</offsets></uri><offsets xml_i="31228" xml_f="31536" txt_i="20817" txt_f="21125">). A concomitant medication was used by 55.0% (72/131) and 53.0% (70/132), respectively, of participants in the placebo and SHP465 MAS groups. The only concomitant ADHD medications used by ≥2% of study participants in either treatment group were lisdexamfetamine, immediate-release MAS, and methylphenidate (</offsets><xref ref-type="supplementary-material" rid="SD1"><offsets xml_i="31586" xml_f="31608" txt_i="21125" txt_f="21147">Supplementary Table S1</offsets></xref><offsets xml_i="31615" xml_f="31765" txt_i="21147" txt_f="21297">); these instances were defined as protocol violations and the number of participants taking these medications was comparable across treatment groups.</offsets></p></sec><sec id="s011"><title><offsets xml_i="31797" xml_f="31810" txt_i="21299" txt_f="21312">Drug exposure</offsets></title><p><offsets xml_i="31821" xml_f="32070" txt_i="21313" txt_f="21562">The mean ± SD duration of exposure was 3.76 ± 0.791 weeks with placebo and 3.77 ± 0.786 weeks with SHP465 MAS. The maximum dose of SHP465 MAS (i.e., the highest dose taken by the participant) was 25 mg in 81.1% (107/132) of participants; only 3.7% (</offsets><italic><offsets xml_i="32078" xml_f="32079" txt_i="21562" txt_f="21563">n</offsets></italic><offsets xml_i="32088" xml_f="32725" txt_i="21563" txt_f="22200"> = 4) of these participants were downtitrated to a final dose of 12.5 mg SHP465 MAS. The optimal dose of SHP465 MAS (i.e., the dose at which a participant was judged by the investigator to have attained an acceptable treatment response) was 25 mg in 72.0% (95/132) of participants and 12.5 mg in 24.2% (32/132) of participants. The mean ± SD adherence rate during the double-blind treatment period ([the number of capsules dispensed minus the number of capsules returned]/[the date the bottle was dispensed of following the visit–the date the bottle was dispensed]) was 99.39% ± 14.127% with placebo and 99.67% ± 13.351% with SHP465 MAS.</offsets></p></sec><sec id="s012"><title><offsets xml_i="32757" xml_f="32765" txt_i="22202" txt_f="22210">Efficacy</offsets></title><p><offsets xml_i="32776" xml_f="32871" txt_i="22211" txt_f="22306">Mean ADHD-RS-IV total score decreased in both treatment groups during the course of the study (</offsets><xref ref-type="fig" rid="f2"><offsets xml_i="32901" xml_f="32908" txt_i="22306" txt_f="22313">Fig. 2A</offsets></xref><offsets xml_i="32915" xml_f="32917" txt_i="22313" txt_f="22315">; </offsets><xref ref-type="supplementary-material" rid="SD2"><offsets xml_i="32967" xml_f="32989" txt_i="22315" txt_f="22337">Supplementary Table S2</offsets></xref><offsets xml_i="32996" xml_f="33356" txt_i="22337" txt_f="22697">). The LS mean (95% CI) change in ADHD-RS-IV total score from baseline to week 4 was −10.8 (−13.0, −8.5) with placebo and −20.7 (−22.9, −18.5) with SHP465 MAS. The LS mean (95% CI) treatment difference for the change from baseline in ADHD-RS-IV total score at week 4 significantly favored SHP465 MAS over placebo (−9.9 [−13.0, −6.8]; degrees of freedom = 241, </offsets><italic><offsets xml_i="33364" xml_f="33365" txt_i="22697" txt_f="22698">t</offsets></italic><offsets xml_i="33374" xml_f="33394" txt_i="22698" txt_f="22718">-statistic = −6.23, </offsets><italic><offsets xml_i="33402" xml_f="33403" txt_i="22718" txt_f="22719">p</offsets></italic><offsets xml_i="33412" xml_f="33521" txt_i="22719" txt_f="22825"> &lt; 0.001; effect size = 0.80). Sensitivity analyses were supportive of the primary MMRM efficacy analysis.</offsets></p><fig id="f2" fig-type="figure" orientation="portrait" position="float"><label><bold><offsets xml_i="33609" xml_f="33616" txt_i="22826" txt_f="22833">FIG. 2.</offsets></bold></label><caption><p><offsets xml_i="33643" xml_f="33676" txt_i="22833" txt_f="22866">Mean ± SD ADHD-RS-IV total score </offsets><bold><offsets xml_i="33682" xml_f="33685" txt_i="22866" txt_f="22869">(A)</offsets></bold><offsets xml_i="33692" xml_f="33709" txt_i="22869" txt_f="22886"> and CGI-I score </offsets><bold><offsets xml_i="33715" xml_f="33718" txt_i="22886" txt_f="22889">(B)</offsets></bold><offsets xml_i="33725" xml_f="33899" txt_i="22889" txt_f="23063"> by treatment week, full analysis set. ADHD-RS-IV, ADHD Rating Scale IV; CGI-I, Clinical Global Impressions-Improvement; MAS, mixed amphetamine salts; SD, standard deviation.</offsets></p></caption><graphic xlink:href="fig-2"></graphic></fig><p><offsets xml_i="33960" xml_f="34031" txt_i="23064" txt_f="23135">Mean CGI-I score decreased in both treatment groups from weeks 1 to 4 (</offsets><xref ref-type="fig" rid="f2"><offsets xml_i="34061" xml_f="34068" txt_i="23135" txt_f="23142">Fig. 2B</offsets></xref><offsets xml_i="34075" xml_f="34077" txt_i="23142" txt_f="23144">; </offsets><xref ref-type="supplementary-material" rid="SD2"><offsets xml_i="34127" xml_f="34149" txt_i="23144" txt_f="23166">Supplementary Table S2</offsets></xref><offsets xml_i="34156" xml_f="34430" txt_i="23166" txt_f="23440">). The LS mean (95% CI) CGI-I score at week 4 was 3.0 (2.8, 3.2) with placebo and 2.2 (2.0, 2.4) with SHP465 MAS. The LS mean (95% CI) treatment difference for CGI-I score at week 4 significantly favored SHP465 MAS over placebo (−0.8 [−1.1, −0.5]; degrees of freedom = 242, </offsets><italic><offsets xml_i="34438" xml_f="34439" txt_i="23440" txt_f="23441">t</offsets></italic><offsets xml_i="34448" xml_f="34468" txt_i="23441" txt_f="23461">-statistic = −5.10, </offsets><italic><offsets xml_i="34476" xml_f="34477" txt_i="23461" txt_f="23462">p</offsets></italic><offsets xml_i="34486" xml_f="34519" txt_i="23462" txt_f="23492"> &lt; 0.001; effect size = 0.65).</offsets></p><p><offsets xml_i="34526" xml_f="34728" txt_i="23493" txt_f="23695">The LS mean (95% CI) treatment differences for the change from baseline at week 4 on the ADHD-RS-IV hyperactivity/impulsivity and inattentiveness subscales favored SHP465 MAS over placebo (both nominal </offsets><italic><offsets xml_i="34736" xml_f="34737" txt_i="23695" txt_f="23696">p</offsets></italic><offsets xml_i="34746" xml_f="34759" txt_i="23696" txt_f="23706"> &lt; 0.001; </offsets><xref ref-type="supplementary-material" rid="SD2"><offsets xml_i="34809" xml_f="34831" txt_i="23706" txt_f="23728">Supplementary Table S2</offsets></xref><offsets xml_i="34838" xml_f="35015" txt_i="23728" txt_f="23905">). On the dichotomized CGI-I, the percentage of participants categorized as improved at the final on-treatment assessment was greater with SHP465 MAS than with placebo (nominal </offsets><italic><offsets xml_i="35023" xml_f="35024" txt_i="23905" txt_f="23906">p</offsets></italic><offsets xml_i="35033" xml_f="35064" txt_i="23906" txt_f="23934"> &lt; 0.001 based on CMH test; </offsets><xref ref-type="supplementary-material" rid="SD2"><offsets xml_i="35114" xml_f="35136" txt_i="23934" txt_f="23956">Supplementary Table S2</offsets></xref><offsets xml_i="35143" xml_f="35145" txt_i="23956" txt_f="23958">).</offsets></p></sec><sec id="s013"><title><offsets xml_i="35177" xml_f="35196" txt_i="23960" txt_f="23979">Safety/tolerability</offsets></title><p><offsets xml_i="35207" xml_f="35277" txt_i="23980" txt_f="24050">The frequency of TEAEs was greater with SHP465 MAS than with placebo (</offsets><xref ref-type="table" rid="T3"><offsets xml_i="35309" xml_f="35316" txt_i="24050" txt_f="24057">Table 3</offsets></xref><offsets xml_i="35323" xml_f="36290" txt_i="24057" txt_f="25021">). Most TEAEs were of mild or moderate severity; there were no on-treatment serious TEAEs reported during the study. There were two nonfatal serious AEs of major depression and suicide attempt in one participant randomized to SHP465 MAS; these AEs occurred 7 days after the final study drug dose. This female participant experienced a TEAE of depressed mood (judged by the investigator to be of mild intensity, not serious, and related to the study drug) after 11 days of treatment, which resulted in study discontinuation. During the follow-up period (7 days after discontinuation of the study drug), the participant experienced serious AEs of major depression (moderate intensity) and suicide attempt (severe intensity). Both serious AEs were not considered to be treatment emergent (they occurred &gt;3 days after cessation of treatment) and were judged by the investigator to be not related to the study drug based on communications with the participant's parent.</offsets></p><p><offsets xml_i="36297" xml_f="36525" txt_i="25022" txt_f="25250">The frequency of TEAEs leading to discontinuation was greater with SHP465 MAS than with placebo. The TEAEs that led to discontinuation were right bundle branch block, acute psychosis, and suicidal ideation in the placebo group (</offsets><italic><offsets xml_i="36533" xml_f="36534" txt_i="25250" txt_f="25251">n</offsets></italic><offsets xml_i="36543" xml_f="36743" txt_i="25251" txt_f="25451"> = 1 for each) and upper abdominal pain, viral infection, increased heart rate, decreased appetite, seizure, depressed mood, insomnia, irritability, hemoptysis, and dizziness in the SHP465 MAS group (</offsets><italic><offsets xml_i="36751" xml_f="36752" txt_i="25451" txt_f="25452">n</offsets></italic><offsets xml_i="36761" xml_f="36855" txt_i="25452" txt_f="25546"> = 1 for each, except for dizziness, which occurred in two participants) (see footnote “†” of </offsets><xref ref-type="table" rid="T2"><offsets xml_i="36887" xml_f="36894" txt_i="25546" txt_f="25553">Table 2</offsets></xref><offsets xml_i="36901" xml_f="37275" txt_i="25553" txt_f="25927">). All TEAEs that led to study discontinuation were reported to be of mild to moderate severity, none were considered to be serious by the study investigator, and only two were not considered to be related to the study drug by the investigator (instances of viral infection and seizure in participants randomized to SHP465 MAS); all TEAEs resolved following discontinuation.</offsets></p><table-wrap id="T2" orientation="portrait" position="float"><label><sc><offsets xml_i="37350" xml_f="37355" txt_i="25928" txt_f="25933">Table</offsets></sc><offsets xml_i="37360" xml_f="37363" txt_i="25933" txt_f="25936"> 2.</offsets></label><caption><p><sc><offsets xml_i="37387" xml_f="37452" txt_i="25936" txt_f="26001">Summary of Safety and Tolerability Endpoints, Safety Analysis Set</offsets></sc></p></caption><table frame="hsides" rules="groups"><colgroup><col align="left"></col><col align="left"></col><col align="left"></col></colgroup><thead><tr><th align="left"><offsets xml_i="37629" xml_f="37630" txt_i="26002" txt_f="26003"> </offsets></th><th align="center"><italic><offsets xml_i="37662" xml_f="37671" txt_i="26003" txt_f="26012">Placebo (</offsets></italic><offsets xml_i="37680" xml_f="37681" txt_i="26012" txt_f="26013">n</offsets><italic><offsets xml_i="37689" xml_f="37696" txt_i="26013" txt_f="26020"> = 131)</offsets></italic></th><th align="center"><italic><offsets xml_i="37737" xml_f="37749" txt_i="26020" txt_f="26032">SHP465 MAS (</offsets></italic><offsets xml_i="37758" xml_f="37759" txt_i="26032" txt_f="26033">n</offsets><italic><offsets xml_i="37767" xml_f="37774" txt_i="26033" txt_f="26040"> = 132)</offsets></italic></th></tr></thead><tbody><tr><td align="left"><offsets xml_i="37829" xml_f="37839" txt_i="26040" txt_f="26050">Any TEAE, </offsets><italic><offsets xml_i="37847" xml_f="37848" txt_i="26050" txt_f="26051">n</offsets></italic><offsets xml_i="37857" xml_f="37861" txt_i="26051" txt_f="26055"> (%)</offsets></td><td align="center"><offsets xml_i="37885" xml_f="37894" txt_i="26056" txt_f="26065">61 (46.6)</offsets></td><td align="center"><offsets xml_i="37918" xml_f="37927" txt_i="26066" txt_f="26075">89 (67.4)</offsets></td></tr><tr><td align="left"><offsets xml_i="37958" xml_f="37990" txt_i="26076" txt_f="26108"> TEAEs related to the study drug</offsets></td><td align="center"><offsets xml_i="38014" xml_f="38023" txt_i="26109" txt_f="26118">34 (26.0)</offsets></td><td align="center"><offsets xml_i="38047" xml_f="38056" txt_i="26119" txt_f="26128">70 (53.0)</offsets></td></tr><tr><td align="left"><offsets xml_i="38087" xml_f="38100" txt_i="26129" txt_f="26142"> Severe TEAEs</offsets><sup><xref ref-type="table-fn" rid="tf4"><offsets xml_i="38141" xml_f="38142" txt_i="26142" txt_f="26143">*</offsets></xref></sup></td><td align="center"><offsets xml_i="38179" xml_f="38186" txt_i="26144" txt_f="26151">1 (0.8)</offsets></td><td align="center"><offsets xml_i="38210" xml_f="38217" txt_i="26152" txt_f="26159">4 (3.0)</offsets></td></tr><tr><td align="left"><offsets xml_i="38248" xml_f="38281" txt_i="26160" txt_f="26193"> TEAEs leading to discontinuation</offsets><sup><xref ref-type="table-fn" rid="tf5"><offsets xml_i="38322" xml_f="38323" txt_i="26193" txt_f="26194">†</offsets></xref></sup></td><td align="center"><offsets xml_i="38360" xml_f="38367" txt_i="26195" txt_f="26202">3 (2.3)</offsets></td><td align="center"><offsets xml_i="38391" xml_f="38399" txt_i="26203" txt_f="26211">11 (8.3)</offsets></td></tr><tr><td align="left"><offsets xml_i="38430" xml_f="38444" txt_i="26212" txt_f="26226"> Serious TEAEs</offsets></td><td align="center"><offsets xml_i="38468" xml_f="38469" txt_i="26227" txt_f="26228">0</offsets></td><td align="center"><offsets xml_i="38493" xml_f="38494" txt_i="26229" txt_f="26230">0</offsets></td></tr><tr><td colspan="3" align="left"><offsets xml_i="38537" xml_f="38593" txt_i="26231" txt_f="26287">TEAEs in ≥2% of participants in either treatment group, </offsets><italic><offsets xml_i="38601" xml_f="38602" txt_i="26287" txt_f="26288">n</offsets></italic><offsets xml_i="38611" xml_f="38615" txt_i="26288" txt_f="26292"> (%)</offsets></td></tr><tr><td align="left"><offsets xml_i="38646" xml_f="38665" txt_i="26293" txt_f="26312"> Decreased appetite</offsets></td><td align="center"><offsets xml_i="38689" xml_f="38696" txt_i="26313" txt_f="26320">9 (6.9)</offsets></td><td align="center"><offsets xml_i="38720" xml_f="38729" txt_i="26321" txt_f="26330">40 (30.3)</offsets></td></tr><tr><td align="left"><offsets xml_i="38760" xml_f="38769" txt_i="26331" txt_f="26340"> Insomnia</offsets><sup><xref ref-type="table-fn" rid="tf6"><offsets xml_i="38810" xml_f="38811" txt_i="26340" txt_f="26341">‡</offsets></xref></sup></td><td align="center"><offsets xml_i="38848" xml_f="38855" txt_i="26342" txt_f="26349">3 (2.3)</offsets></td><td align="center"><offsets xml_i="38879" xml_f="38888" txt_i="26350" txt_f="26359">22 (16.7)</offsets></td></tr><tr><td align="left"><offsets xml_i="38919" xml_f="38928" txt_i="26360" txt_f="26369"> Headache</offsets></td><td align="center"><offsets xml_i="38952" xml_f="38961" txt_i="26370" txt_f="26379">14 (10.7)</offsets></td><td align="center"><offsets xml_i="38985" xml_f="38994" txt_i="26380" txt_f="26389">16 (12.1)</offsets></td></tr><tr><td align="left"><offsets xml_i="39025" xml_f="39038" txt_i="26390" txt_f="26403"> Irritability</offsets></td><td align="center"><offsets xml_i="39062" xml_f="39069" txt_i="26404" txt_f="26411">2 (1.5)</offsets></td><td align="center"><offsets xml_i="39093" xml_f="39100" txt_i="26412" txt_f="26419">9 (6.8)</offsets></td></tr><tr><td align="left"><offsets xml_i="39131" xml_f="39138" txt_i="26420" txt_f="26427"> Nausea</offsets></td><td align="center"><offsets xml_i="39162" xml_f="39169" txt_i="26428" txt_f="26435">4 (3.1)</offsets></td><td align="center"><offsets xml_i="39193" xml_f="39200" txt_i="26436" txt_f="26443">9 (6.8)</offsets></td></tr><tr><td align="left"><offsets xml_i="39231" xml_f="39248" txt_i="26444" txt_f="26461"> Weight decreased</offsets></td><td align="center"><offsets xml_i="39272" xml_f="39279" txt_i="26462" txt_f="26469">1 (0.8)</offsets></td><td align="center"><offsets xml_i="39303" xml_f="39310" txt_i="26470" txt_f="26477">7 (5.3)</offsets></td></tr><tr><td align="left"><offsets xml_i="39341" xml_f="39351" txt_i="26478" txt_f="26488"> Dizziness</offsets></td><td align="center"><offsets xml_i="39375" xml_f="39376" txt_i="26489" txt_f="26490">0</offsets></td><td align="center"><offsets xml_i="39400" xml_f="39407" txt_i="26491" txt_f="26498">6 (4.5)</offsets></td></tr><tr><td align="left"><offsets xml_i="39438" xml_f="39459" txt_i="26499" txt_f="26520"> Heart rate increased</offsets></td><td align="center"><offsets xml_i="39483" xml_f="39490" txt_i="26521" txt_f="26528">1 (0.8)</offsets></td><td align="center"><offsets xml_i="39514" xml_f="39521" txt_i="26529" txt_f="26536">5 (3.8)</offsets></td></tr><tr><td align="left"><offsets xml_i="39552" xml_f="39573" txt_i="26537" txt_f="26558"> Abdominal pain upper</offsets></td><td align="center"><offsets xml_i="39597" xml_f="39604" txt_i="26559" txt_f="26566">2 (1.5)</offsets></td><td align="center"><offsets xml_i="39628" xml_f="39635" txt_i="26567" txt_f="26574">4 (3.0)</offsets></td></tr><tr><td align="left"><offsets xml_i="39666" xml_f="39700" txt_i="26575" txt_f="26609"> Upper respiratory tract infection</offsets></td><td align="center"><offsets xml_i="39724" xml_f="39731" txt_i="26610" txt_f="26617">2 (1.5)</offsets></td><td align="center"><offsets xml_i="39755" xml_f="39762" txt_i="26618" txt_f="26625">3 (2.3)</offsets></td></tr><tr><td align="left"><offsets xml_i="39793" xml_f="39801" txt_i="26626" txt_f="26634"> Fatigue</offsets></td><td align="center"><offsets xml_i="39825" xml_f="39832" txt_i="26635" txt_f="26642">4 (3.1)</offsets></td><td align="center"><offsets xml_i="39856" xml_f="39863" txt_i="26643" txt_f="26650">2 (1.5)</offsets></td></tr><tr><td align="left"><offsets xml_i="39894" xml_f="39910" txt_i="26651" txt_f="26667"> Nasopharyngitis</offsets></td><td align="center"><offsets xml_i="39934" xml_f="39941" txt_i="26668" txt_f="26675">4 (3.1)</offsets></td><td align="center"><offsets xml_i="39965" xml_f="39966" txt_i="26676" txt_f="26677">0</offsets></td></tr><tr><td align="left"><offsets xml_i="39997" xml_f="40016" txt_i="26678" txt_f="26697"> Oropharyngeal pain</offsets></td><td align="center"><offsets xml_i="40040" xml_f="40047" txt_i="26698" txt_f="26705">3 (2.3)</offsets></td><td align="center"><offsets xml_i="40071" xml_f="40072" txt_i="26706" txt_f="26707">0</offsets></td></tr><tr><td align="left"><offsets xml_i="40103" xml_f="40120" txt_i="26708" txt_f="26725"> Weight increased</offsets></td><td align="center"><offsets xml_i="40144" xml_f="40151" txt_i="26726" txt_f="26733">3 (2.3)</offsets></td><td align="center"><offsets xml_i="40175" xml_f="40176" txt_i="26734" txt_f="26735">0</offsets></td></tr><tr><td colspan="3" align="left"><offsets xml_i="40219" xml_f="40281" txt_i="26736" txt_f="26798">Vital signs, mean ± SD change at final on-treatment assessment</offsets><sup><xref ref-type="table-fn" rid="tf7"><offsets xml_i="40322" xml_f="40323" txt_i="26798" txt_f="26799">¶</offsets></xref></sup></td></tr><tr><td align="left"><offsets xml_i="40367" xml_f="40377" txt_i="26800" txt_f="26810"> SBP, mmHg</offsets></td><td align="center"><offsets xml_i="40401" xml_f="40411" txt_i="26811" txt_f="26821">2.1 ± 8.72</offsets></td><td align="center"><offsets xml_i="40435" xml_f="40445" txt_i="26822" txt_f="26832">3.8 ± 9.15</offsets></td></tr><tr><td align="left"><offsets xml_i="40476" xml_f="40486" txt_i="26833" txt_f="26843"> DBP, mmHg</offsets></td><td align="center"><offsets xml_i="40510" xml_f="40520" txt_i="26844" txt_f="26854">0.5 ± 7.45</offsets></td><td align="center"><offsets xml_i="40544" xml_f="40554" txt_i="26855" txt_f="26865">4.0 ± 8.23</offsets></td></tr><tr><td align="left"><offsets xml_i="40585" xml_f="40596" txt_i="26866" txt_f="26877"> Pulse, bpm</offsets></td><td align="center"><offsets xml_i="40620" xml_f="40631" txt_i="26878" txt_f="26889">0.7 ± 10.79</offsets></td><td align="center"><offsets xml_i="40655" xml_f="40666" txt_i="26890" txt_f="26901">5.7 ± 11.78</offsets></td></tr><tr><td colspan="3" align="left"><offsets xml_i="40709" xml_f="40758" txt_i="26902" txt_f="26951">Vital sign outliers at any time during treatment,</offsets><sup><xref ref-type="table-fn" rid="tf8"><offsets xml_i="40799" xml_f="40800" txt_i="26951" txt_f="26952">§</offsets></xref></sup><italic><offsets xml_i="40821" xml_f="40822" txt_i="26952" txt_f="26953">n</offsets></italic><offsets xml_i="40831" xml_f="40835" txt_i="26953" txt_f="26957"> (%)</offsets></td></tr><tr><td align="left"><offsets xml_i="40866" xml_f="40937" txt_i="26958" txt_f="27023"> SBP &gt;120 mmHg and increase of &gt;10 mmHg from baseline in children</offsets></td><td align="center"><offsets xml_i="40961" xml_f="40968" txt_i="27024" txt_f="27031">3 (6.0)</offsets></td><td align="center"><offsets xml_i="40992" xml_f="40999" txt_i="27032" txt_f="27039">4 (7.8)</offsets></td></tr><tr><td align="left"><offsets xml_i="41030" xml_f="41104" txt_i="27040" txt_f="27108"> SBP &gt;140 mmHg and increase of &gt;10 mmHg from baseline in adolescents</offsets></td><td align="center"><offsets xml_i="41128" xml_f="41129" txt_i="27109" txt_f="27110">0</offsets></td><td align="center"><offsets xml_i="41153" xml_f="41160" txt_i="27111" txt_f="27118">1 (1.3)</offsets></td></tr><tr><td align="left"><offsets xml_i="41191" xml_f="41261" txt_i="27119" txt_f="27183"> DBP &gt;80 mmHg and increase of &gt;10 mmHg from baseline in children</offsets></td><td align="center"><offsets xml_i="41285" xml_f="41292" txt_i="27184" txt_f="27191">3 (6.0)</offsets></td><td align="center"><offsets xml_i="41316" xml_f="41323" txt_i="27192" txt_f="27199">3 (5.9)</offsets></td></tr><tr><td align="left"><offsets xml_i="41354" xml_f="41427" txt_i="27200" txt_f="27267"> DBP &gt;90 mmHg and increase of &gt;10 mmHg from baseline in adolescents</offsets></td><td align="center"><offsets xml_i="41451" xml_f="41452" txt_i="27268" txt_f="27269">0</offsets></td><td align="center"><offsets xml_i="41476" xml_f="41483" txt_i="27270" txt_f="27277">1 (1.3)</offsets></td></tr><tr><td align="left"><offsets xml_i="41514" xml_f="41584" txt_i="27278" txt_f="27345"> Pulse rate ≥100 bpm and increase &gt;15 bpm from baseline in children</offsets></td><td align="center"><offsets xml_i="41608" xml_f="41615" txt_i="27346" txt_f="27353">1 (2.0)</offsets></td><td align="center"><offsets xml_i="41639" xml_f="41647" txt_i="27354" txt_f="27362">9 (17.6)</offsets></td></tr><tr><td align="left"><offsets xml_i="41678" xml_f="41751" txt_i="27363" txt_f="27433"> Pulse rate ≥100 bpm and increase &gt;15 bpm from baseline in adolescents</offsets></td><td align="center"><offsets xml_i="41775" xml_f="41782" txt_i="27434" txt_f="27441">2 (2.5)</offsets></td><td align="center"><offsets xml_i="41806" xml_f="41813" txt_i="27442" txt_f="27449">5 (6.5)</offsets></td></tr><tr><td colspan="3" align="left"><offsets xml_i="41856" xml_f="41895" txt_i="27450" txt_f="27489">Weight at final on-treatment assessment</offsets><sup><xref ref-type="table-fn" rid="tf7"><offsets xml_i="41936" xml_f="41937" txt_i="27489" txt_f="27490">¶</offsets></xref></sup></td></tr><tr><td align="left"><offsets xml_i="41981" xml_f="42035" txt_i="27491" txt_f="27545"> Mean ± SD change at final on-treatment assessment, kg</offsets></td><td align="center"><offsets xml_i="42059" xml_f="42071" txt_i="27546" txt_f="27558">0.70 ± 1.256</offsets></td><td align="center"><offsets xml_i="42095" xml_f="42108" txt_i="27559" txt_f="27572">−0.92 ± 1.480</offsets></td></tr><tr><td align="left"><offsets xml_i="42139" xml_f="42150" txt_i="27573" txt_f="27584"> Mean ± SD </offsets><italic><offsets xml_i="42158" xml_f="42159" txt_i="27584" txt_f="27585">z</offsets></italic><offsets xml_i="42168" xml_f="42174" txt_i="27585" txt_f="27591">-score</offsets></td><td align="center"><offsets xml_i="42198" xml_f="42210" txt_i="27592" txt_f="27604">0.04 ± 0.138</offsets></td><td align="center"><offsets xml_i="42234" xml_f="42247" txt_i="27605" txt_f="27618">−0.12 ± 0.164</offsets></td></tr><tr><td align="left"><offsets xml_i="42278" xml_f="42286" txt_i="27619" txt_f="27627"> Median </offsets><italic><offsets xml_i="42294" xml_f="42295" txt_i="27627" txt_f="27628">z</offsets></italic><offsets xml_i="42304" xml_f="42310" txt_i="27628" txt_f="27634">-score</offsets></td><td align="center"><offsets xml_i="42334" xml_f="42338" txt_i="27635" txt_f="27639">0.04</offsets></td><td align="center"><offsets xml_i="42362" xml_f="42367" txt_i="27640" txt_f="27645">−0.11</offsets></td></tr><tr><td align="left"><offsets xml_i="42398" xml_f="42434" txt_i="27646" txt_f="27682"> Weight decrease ≥7% from baseline, </offsets><italic><offsets xml_i="42442" xml_f="42443" txt_i="27682" txt_f="27683">n</offsets></italic><offsets xml_i="42452" xml_f="42456" txt_i="27683" txt_f="27687"> (%)</offsets></td><td align="center"><offsets xml_i="42480" xml_f="42487" txt_i="27688" txt_f="27695">2 (1.6)</offsets></td><td align="center"><offsets xml_i="42511" xml_f="42518" txt_i="27696" txt_f="27703">7 (5.5)</offsets></td></tr><tr><td colspan="3" align="left"><offsets xml_i="42561" xml_f="42597" txt_i="27704" txt_f="27740">BMI at final on-treatment assessment</offsets><sup><xref ref-type="table-fn" rid="tf7"><offsets xml_i="42638" xml_f="42639" txt_i="27740" txt_f="27741">¶</offsets></xref></sup></td></tr><tr><td align="left"><offsets xml_i="42683" xml_f="42739" txt_i="27742" txt_f="27798"> Mean ± SD change at final on-treatment assessment, kg/m</offsets><sup><offsets xml_i="42744" xml_f="42745" txt_i="27798" txt_f="27799">2</offsets></sup></td><td align="center"><offsets xml_i="42775" xml_f="42787" txt_i="27800" txt_f="27812">0.30 ± 0.541</offsets></td><td align="center"><offsets xml_i="42811" xml_f="42824" txt_i="27813" txt_f="27826">−0.37 ± 0.576</offsets></td></tr><tr><td align="left"><offsets xml_i="42855" xml_f="42866" txt_i="27827" txt_f="27838"> Mean ± SD </offsets><italic><offsets xml_i="42874" xml_f="42875" txt_i="27838" txt_f="27839">z</offsets></italic><offsets xml_i="42884" xml_f="42890" txt_i="27839" txt_f="27845">-score</offsets></td><td align="center"><offsets xml_i="42914" xml_f="42926" txt_i="27846" txt_f="27858">0.08 ± 0.185</offsets></td><td align="center"><offsets xml_i="42950" xml_f="42963" txt_i="27859" txt_f="27872">−0.14 ± 0.251</offsets></td></tr><tr><td align="left"><offsets xml_i="42994" xml_f="43002" txt_i="27873" txt_f="27881"> Median </offsets><italic><offsets xml_i="43010" xml_f="43011" txt_i="27881" txt_f="27882">z</offsets></italic><offsets xml_i="43020" xml_f="43026" txt_i="27882" txt_f="27888">-score</offsets></td><td align="center"><offsets xml_i="43050" xml_f="43054" txt_i="27889" txt_f="27893">0.06</offsets></td><td align="center"><offsets xml_i="43078" xml_f="43083" txt_i="27894" txt_f="27899">−0.10</offsets></td></tr></tbody></table><table-wrap-foot><fn id="tf4"><label><sup><offsets xml_i="43151" xml_f="43152" txt_i="27900" txt_f="27901">*</offsets></sup></label><p><offsets xml_i="43169" xml_f="43207" txt_i="27901" txt_f="27939">Severe TEAEs: placebo (muscle strain [</offsets><italic><offsets xml_i="43215" xml_f="43216" txt_i="27939" txt_f="27940">n</offsets></italic><offsets xml_i="43225" xml_f="43253" txt_i="27940" txt_f="27968"> = 1]); SHP465 MAS (nausea [</offsets><italic><offsets xml_i="43261" xml_f="43262" txt_i="27968" txt_f="27969">n</offsets></italic><offsets xml_i="43271" xml_f="43289" txt_i="27969" txt_f="27987"> = 1]; back pain [</offsets><italic><offsets xml_i="43297" xml_f="43298" txt_i="27987" txt_f="27988">n</offsets></italic><offsets xml_i="43307" xml_f="43325" txt_i="27988" txt_f="28006"> = 1]; neck pain [</offsets><italic><offsets xml_i="43333" xml_f="43334" txt_i="28006" txt_f="28007">n</offsets></italic><offsets xml_i="43343" xml_f="43361" txt_i="28007" txt_f="28025"> = 1]; dizziness [</offsets><italic><offsets xml_i="43369" xml_f="43370" txt_i="28025" txt_f="28026">n</offsets></italic><offsets xml_i="43379" xml_f="43400" txt_i="28026" txt_f="28047"> = 1]; and lethargy [</offsets><italic><offsets xml_i="43408" xml_f="43409" txt_i="28047" txt_f="28048">n</offsets></italic><offsets xml_i="43418" xml_f="43435" txt_i="28048" txt_f="28065"> = 1]; insomnia [</offsets><italic><offsets xml_i="43443" xml_f="43444" txt_i="28065" txt_f="28066">n</offsets></italic><offsets xml_i="43453" xml_f="43460" txt_i="28066" txt_f="28073"> = 1]).</offsets></p></fn><fn id="tf5"><label><sup><offsets xml_i="43494" xml_f="43495" txt_i="28074" txt_f="28075">†</offsets></sup></label><p><offsets xml_i="43512" xml_f="43582" txt_i="28075" txt_f="28145">TEAEs leading to discontinuation: placebo (bundle branch block right [</offsets><italic><offsets xml_i="43590" xml_f="43591" txt_i="28145" txt_f="28146">n</offsets></italic><offsets xml_i="43600" xml_f="43624" txt_i="28146" txt_f="28170"> = 1]; acute psychosis [</offsets><italic><offsets xml_i="43632" xml_f="43633" txt_i="28170" txt_f="28171">n</offsets></italic><offsets xml_i="43642" xml_f="43672" txt_i="28171" txt_f="28201"> = 1]; and suicidal ideation [</offsets><italic><offsets xml_i="43680" xml_f="43681" txt_i="28201" txt_f="28202">n</offsets></italic><offsets xml_i="43690" xml_f="43732" txt_i="28202" txt_f="28244"> = 1]); SHP465 MAS (abdominal pain upper [</offsets><italic><offsets xml_i="43740" xml_f="43741" txt_i="28244" txt_f="28245">n</offsets></italic><offsets xml_i="43750" xml_f="43774" txt_i="28245" txt_f="28269"> = 1]; viral infection [</offsets><italic><offsets xml_i="43782" xml_f="43783" txt_i="28269" txt_f="28270">n</offsets></italic><offsets xml_i="43792" xml_f="43821" txt_i="28270" txt_f="28299"> = 1]; heart rate increased [</offsets><italic><offsets xml_i="43829" xml_f="43830" txt_i="28299" txt_f="28300">n</offsets></italic><offsets xml_i="43839" xml_f="43866" txt_i="28300" txt_f="28327"> = 1]; decreased appetite [</offsets><italic><offsets xml_i="43874" xml_f="43875" txt_i="28327" txt_f="28328">n</offsets></italic><offsets xml_i="43884" xml_f="43902" txt_i="28328" txt_f="28346"> = 1]; dizziness [</offsets><italic><offsets xml_i="43910" xml_f="43911" txt_i="28346" txt_f="28347">n</offsets></italic><offsets xml_i="43920" xml_f="43936" txt_i="28347" txt_f="28363"> = 2]; seizure [</offsets><italic><offsets xml_i="43944" xml_f="43945" txt_i="28363" txt_f="28364">n</offsets></italic><offsets xml_i="43954" xml_f="43977" txt_i="28364" txt_f="28387"> = 1]; depressed mood [</offsets><italic><offsets xml_i="43985" xml_f="43986" txt_i="28387" txt_f="28388">n</offsets></italic><offsets xml_i="43995" xml_f="44012" txt_i="28388" txt_f="28405"> = 1]; insomnia [</offsets><italic><offsets xml_i="44020" xml_f="44021" txt_i="28405" txt_f="28406">n</offsets></italic><offsets xml_i="44030" xml_f="44051" txt_i="28406" txt_f="28427"> = 1]; irritability [</offsets><italic><offsets xml_i="44059" xml_f="44060" txt_i="28427" txt_f="28428">n</offsets></italic><offsets xml_i="44069" xml_f="44092" txt_i="28428" txt_f="28451"> = 1]; and hemoptysis [</offsets><italic><offsets xml_i="44100" xml_f="44101" txt_i="28451" txt_f="28452">n</offsets></italic><offsets xml_i="44110" xml_f="44117" txt_i="28452" txt_f="28459"> = 1]).</offsets></p></fn><fn id="tf6"><label><sup><offsets xml_i="44151" xml_f="44152" txt_i="28460" txt_f="28461">‡</offsets></sup></label><p><offsets xml_i="44169" xml_f="44245" txt_i="28461" txt_f="28537">Includes preferred terms of insomnia, initial insomnia, and middle insomnia.</offsets></p></fn><fn id="tf7"><label><sup><offsets xml_i="44279" xml_f="44280" txt_i="28538" txt_f="28539">¶</offsets></sup></label><p><offsets xml_i="44297" xml_f="44306" txt_i="28539" txt_f="28548">Based on </offsets><italic><offsets xml_i="44314" xml_f="44315" txt_i="28548" txt_f="28549">n</offsets></italic><offsets xml_i="44324" xml_f="44347" txt_i="28549" txt_f="28572"> = 129 for placebo and </offsets><italic><offsets xml_i="44355" xml_f="44356" txt_i="28572" txt_f="28573">n</offsets></italic><offsets xml_i="44365" xml_f="44387" txt_i="28573" txt_f="28595"> = 128 for SHP465 MAS.</offsets></p></fn><fn id="tf8"><label><sup><offsets xml_i="44421" xml_f="44422" txt_i="28596" txt_f="28597">§</offsets></sup></label><p><offsets xml_i="44439" xml_f="44448" txt_i="28597" txt_f="28606">Based on </offsets><italic><offsets xml_i="44456" xml_f="44457" txt_i="28606" txt_f="28607">n</offsets></italic><offsets xml_i="44466" xml_f="44485" txt_i="28607" txt_f="28626"> = 50 children and </offsets><italic><offsets xml_i="44493" xml_f="44494" txt_i="28626" txt_f="28627">n</offsets></italic><offsets xml_i="44503" xml_f="44538" txt_i="28627" txt_f="28662"> = 79 adolescents for placebo, and </offsets><italic><offsets xml_i="44546" xml_f="44547" txt_i="28662" txt_f="28663">n</offsets></italic><offsets xml_i="44556" xml_f="44575" txt_i="28663" txt_f="28682"> = 51 children and </offsets><italic><offsets xml_i="44583" xml_f="44584" txt_i="28682" txt_f="28683">n</offsets></italic><offsets xml_i="44593" xml_f="44626" txt_i="28683" txt_f="28716"> = 77 adolescents for SHP465 MAS.</offsets></p></fn><fn id="tf9"><p><offsets xml_i="44651" xml_f="44827" txt_i="28717" txt_f="28893">BMI, body mass index; DBP, diastolic blood pressure; MAS, mixed amphetamine salts; SBP, systolic blood pressure; SD, standard deviation; TEAE, treatment-emergent adverse event.</offsets></p></fn></table-wrap-foot></table-wrap><p><offsets xml_i="44870" xml_f="45156" txt_i="28894" txt_f="29180">The most frequently reported TEAEs (those reported by ≥2% of participants) in the SHP465 MAS treatment arm were decreased appetite, insomnia, headache, irritability, nausea, weight decreased, dizziness, heart rate increased, upper abdominal pain, and upper respiratory tract infection (</offsets><xref ref-type="table" rid="T2"><offsets xml_i="45188" xml_f="45195" txt_i="29180" txt_f="29187">Table 2</offsets></xref><offsets xml_i="45202" xml_f="45478" txt_i="29187" txt_f="29463">). Decreased appetite and insomnia were the most frequently reported TEAEs with SHP465 MAS. The majority of instances of TEAEs related to decreased appetite or insomnia were of mild or moderate intensity, resolved while on the study drug, and did not result in a dose change (</offsets><xref ref-type="table" rid="T3"><offsets xml_i="45510" xml_f="45517" txt_i="29463" txt_f="29470">Table 3</offsets></xref><offsets xml_i="45524" xml_f="45820" txt_i="29470" txt_f="29766">). The mean number of events per individual, mean onset day of events, and mean event duration while on the study drug were roughly comparable for both TEAE types across treatments, with the exception of onset day for decreased appetite that tended to be lower with SHP465 MAS than with placebo (</offsets><xref ref-type="table" rid="T3"><offsets xml_i="45852" xml_f="45859" txt_i="29766" txt_f="29773">Table 3</offsets></xref><offsets xml_i="45866" xml_f="45868" txt_i="29773" txt_f="29775">).</offsets></p><table-wrap id="T3" orientation="portrait" position="float"><label><sc><offsets xml_i="45943" xml_f="45948" txt_i="29776" txt_f="29781">Table</offsets></sc><offsets xml_i="45953" xml_f="45956" txt_i="29781" txt_f="29784"> 3.</offsets></label><caption><p><sc><offsets xml_i="45980" xml_f="46093" txt_i="29784" txt_f="29897">Summary of Insomnia-Related and Decreased Appetite-Related Treatment-Emergent Adverse Events, Safety Analysis Set</offsets></sc></p></caption><table frame="hsides" rules="groups"><colgroup><col align="left"></col><col align="left"></col><col align="left"></col><col align="left"></col><col align="left"></col></colgroup><thead><tr><th align="left"><offsets xml_i="46318" xml_f="46319" txt_i="29898" txt_f="29899"> </offsets></th><th colspan="2" align="center"><italic><offsets xml_i="46363" xml_f="46371" txt_i="29899" txt_f="29907">Insomnia</offsets><sup><xref ref-type="table-fn" rid="tf10"><offsets xml_i="46413" xml_f="46414" txt_i="29907" txt_f="29908">*</offsets></xref></sup></italic></th><th colspan="2" align="center"><italic><offsets xml_i="46480" xml_f="46498" txt_i="29908" txt_f="29926">Decreased appetite</offsets></italic></th></tr><tr><th align="left"><offsets xml_i="46538" xml_f="46539" txt_i="29926" txt_f="29927"> </offsets></th><th align="center"><italic><offsets xml_i="46571" xml_f="46580" txt_i="29927" txt_f="29936">Placebo (</offsets></italic><offsets xml_i="46589" xml_f="46590" txt_i="29936" txt_f="29937">n</offsets><italic><offsets xml_i="46598" xml_f="46605" txt_i="29937" txt_f="29944"> = 131)</offsets></italic></th><th align="center"><italic><offsets xml_i="46646" xml_f="46658" txt_i="29944" txt_f="29956">SHP465 MAS (</offsets></italic><offsets xml_i="46667" xml_f="46668" txt_i="29956" txt_f="29957">n</offsets><italic><offsets xml_i="46676" xml_f="46683" txt_i="29957" txt_f="29964"> = 132)</offsets></italic></th><th align="center"><italic><offsets xml_i="46724" xml_f="46733" txt_i="29964" txt_f="29973">Placebo (</offsets></italic><offsets xml_i="46742" xml_f="46743" txt_i="29973" txt_f="29974">n</offsets><italic><offsets xml_i="46751" xml_f="46758" txt_i="29974" txt_f="29981"> = 131)</offsets></italic></th><th align="center"><italic><offsets xml_i="46799" xml_f="46811" txt_i="29981" txt_f="29993">SHP465 MAS (</offsets></italic><offsets xml_i="46820" xml_f="46821" txt_i="29993" txt_f="29994">n</offsets><italic><offsets xml_i="46829" xml_f="46836" txt_i="29994" txt_f="30001"> = 132)</offsets></italic></th></tr></thead><tbody><tr><td align="left"><offsets xml_i="46891" xml_f="46916" txt_i="30001" txt_f="30026">Participants with event, </offsets><italic><offsets xml_i="46924" xml_f="46925" txt_i="30026" txt_f="30027">n</offsets></italic><offsets xml_i="46934" xml_f="46938" txt_i="30027" txt_f="30031"> (%)</offsets></td><td align="center"><offsets xml_i="46962" xml_f="46969" txt_i="30032" txt_f="30039">3 (2.3)</offsets></td><td align="center"><offsets xml_i="46993" xml_f="47002" txt_i="30040" txt_f="30049">22 (16.7)</offsets></td><td align="center"><offsets xml_i="47026" xml_f="47033" txt_i="30050" txt_f="30057">9 (6.9)</offsets></td><td align="center"><offsets xml_i="47057" xml_f="47066" txt_i="30058" txt_f="30067">40 (30.5)</offsets></td></tr><tr><td align="left"><offsets xml_i="47097" xml_f="47113" txt_i="30068" txt_f="30084">Number of events</offsets></td><td align="center"><offsets xml_i="47137" xml_f="47138" txt_i="30085" txt_f="30086">3</offsets></td><td align="center"><offsets xml_i="47162" xml_f="47164" txt_i="30087" txt_f="30089">27</offsets></td><td align="center"><offsets xml_i="47188" xml_f="47189" txt_i="30090" txt_f="30091">9</offsets></td><td align="center"><offsets xml_i="47213" xml_f="47215" txt_i="30092" txt_f="30094">44</offsets></td></tr><tr><td align="left"><offsets xml_i="47246" xml_f="47287" txt_i="30095" txt_f="30136">Mean ± SD number of events per individual</offsets><sup><xref ref-type="table-fn" rid="tf11"><offsets xml_i="47329" xml_f="47330" txt_i="30136" txt_f="30137">†</offsets></xref></sup></td><td align="center"><offsets xml_i="47367" xml_f="47374" txt_i="30138" txt_f="30145">1.0 ± 0</offsets></td><td align="center"><offsets xml_i="47398" xml_f="47408" txt_i="30146" txt_f="30156">1.2 ± 0.53</offsets></td><td align="center"><offsets xml_i="47432" xml_f="47439" txt_i="30157" txt_f="30164">1.0 ± 0</offsets></td><td align="center"><offsets xml_i="47463" xml_f="47473" txt_i="30165" txt_f="30175">1.1 ± 0.38</offsets></td></tr><tr><td align="left"><offsets xml_i="47504" xml_f="47532" txt_i="30176" txt_f="30204">Mean ± SD onset day of event</offsets><sup><xref ref-type="table-fn" rid="tf12"><offsets xml_i="47574" xml_f="47575" txt_i="30204" txt_f="30205">‡</offsets></xref></sup></td><td align="center"><offsets xml_i="47612" xml_f="47622" txt_i="30206" txt_f="30216">6.3 ± 9.24</offsets></td><td align="center"><offsets xml_i="47646" xml_f="47656" txt_i="30217" txt_f="30227">6.8 ± 6.36</offsets></td><td align="center"><offsets xml_i="47680" xml_f="47690" txt_i="30228" txt_f="30238">6.4 ± 4.28</offsets></td><td align="center"><offsets xml_i="47714" xml_f="47724" txt_i="30239" txt_f="30249">4.4 ± 4.52</offsets></td></tr><tr><td align="left"><offsets xml_i="47755" xml_f="47814" txt_i="30250" txt_f="30309">Mean ± SD duration of event while on the study drug in days</offsets><sup><xref ref-type="table-fn" rid="tf11"><offsets xml_i="47856" xml_f="47857" txt_i="30309" txt_f="30310">†</offsets></xref></sup></td><td align="center"><offsets xml_i="47894" xml_f="47905" txt_i="30311" txt_f="30322">13.3 ± 2.89</offsets></td><td align="center"><offsets xml_i="47929" xml_f="47940" txt_i="30323" txt_f="30334">12.1 ± 8.53</offsets></td><td align="center"><offsets xml_i="47964" xml_f="47975" txt_i="30335" txt_f="30346">19.4 ± 7.58</offsets></td><td align="center"><offsets xml_i="47999" xml_f="48010" txt_i="30347" txt_f="30358">19.8 ± 9.50</offsets></td></tr><tr><td colspan="5" align="left"><offsets xml_i="48053" xml_f="48072" txt_i="30359" txt_f="30378">Severity of event, </offsets><italic><offsets xml_i="48080" xml_f="48081" txt_i="30378" txt_f="30379">n</offsets></italic><offsets xml_i="48090" xml_f="48094" txt_i="30379" txt_f="30383"> (%)</offsets></td></tr><tr><td align="left"><offsets xml_i="48125" xml_f="48130" txt_i="30384" txt_f="30389"> Mild</offsets></td><td align="center"><offsets xml_i="48154" xml_f="48162" txt_i="30390" txt_f="30398">2 (66.7)</offsets></td><td align="center"><offsets xml_i="48186" xml_f="48195" txt_i="30399" txt_f="30408">14 (51.9)</offsets></td><td align="center"><offsets xml_i="48219" xml_f="48227" txt_i="30409" txt_f="30417">6 (66.7)</offsets></td><td align="center"><offsets xml_i="48251" xml_f="48260" txt_i="30418" txt_f="30427">26 (59.1)</offsets></td></tr><tr><td align="left"><offsets xml_i="48291" xml_f="48300" txt_i="30428" txt_f="30437"> Moderate</offsets></td><td align="center"><offsets xml_i="48324" xml_f="48332" txt_i="30438" txt_f="30446">1 (33.3)</offsets></td><td align="center"><offsets xml_i="48356" xml_f="48365" txt_i="30447" txt_f="30456">12 (44.4)</offsets></td><td align="center"><offsets xml_i="48389" xml_f="48397" txt_i="30457" txt_f="30465">3 (33.3)</offsets></td><td align="center"><offsets xml_i="48421" xml_f="48430" txt_i="30466" txt_f="30475">18 (40.9)</offsets></td></tr><tr><td align="left"><offsets xml_i="48461" xml_f="48468" txt_i="30476" txt_f="30483"> Severe</offsets></td><td align="center"><offsets xml_i="48492" xml_f="48493" txt_i="30484" txt_f="30485">0</offsets></td><td align="center"><offsets xml_i="48517" xml_f="48524" txt_i="30486" txt_f="30493">1 (3.7)</offsets></td><td align="center"><offsets xml_i="48548" xml_f="48549" txt_i="30494" txt_f="30495">0</offsets></td><td align="center"><offsets xml_i="48573" xml_f="48574" txt_i="30496" txt_f="30497">0</offsets></td></tr><tr><td colspan="5" align="left"><offsets xml_i="48617" xml_f="48635" txt_i="30498" txt_f="30516">Outcome of event, </offsets><italic><offsets xml_i="48643" xml_f="48644" txt_i="30516" txt_f="30517">n</offsets></italic><offsets xml_i="48653" xml_f="48657" txt_i="30517" txt_f="30521"> (%)</offsets></td></tr><tr><td align="left"><offsets xml_i="48688" xml_f="48697" txt_i="30522" txt_f="30531"> Resolved</offsets><sup><xref ref-type="table-fn" rid="tf13"><offsets xml_i="48739" xml_f="48740" txt_i="30531" txt_f="30532">§</offsets></xref></sup></td><td align="center"><offsets xml_i="48777" xml_f="48784" txt_i="30533" txt_f="30540">3 (100)</offsets></td><td align="center"><offsets xml_i="48808" xml_f="48817" txt_i="30541" txt_f="30550">26 (96.3)</offsets></td><td align="center"><offsets xml_i="48841" xml_f="48849" txt_i="30551" txt_f="30559">8 (88.9)</offsets></td><td align="center"><offsets xml_i="48873" xml_f="48882" txt_i="30560" txt_f="30569">38 (86.4)</offsets></td></tr><tr><td align="left"><offsets xml_i="48913" xml_f="48921" txt_i="30570" txt_f="30578"> Ongoing</offsets><sup><xref ref-type="table-fn" rid="tf14"><offsets xml_i="48963" xml_f="48964" txt_i="30578" txt_f="30579">¶</offsets></xref></sup></td><td align="center"><offsets xml_i="49001" xml_f="49002" txt_i="30580" txt_f="30581">0</offsets></td><td align="center"><offsets xml_i="49026" xml_f="49033" txt_i="30582" txt_f="30589">1 (3.7)</offsets></td><td align="center"><offsets xml_i="49057" xml_f="49065" txt_i="30590" txt_f="30598">1 (11.1)</offsets></td><td align="center"><offsets xml_i="49089" xml_f="49097" txt_i="30599" txt_f="30607">5 (11.6)</offsets></td></tr><tr><td colspan="5" align="left"><offsets xml_i="49140" xml_f="49157" txt_i="30608" txt_f="30625">Dose adjustment, </offsets><italic><offsets xml_i="49165" xml_f="49166" txt_i="30625" txt_f="30626">n</offsets></italic><offsets xml_i="49175" xml_f="49179" txt_i="30626" txt_f="30630"> (%)</offsets><sup><xref ref-type="table-fn" rid="tf15"><offsets xml_i="49221" xml_f="49222" txt_i="30630" txt_f="30631">£</offsets></xref></sup></td></tr><tr><td align="left"><offsets xml_i="49266" xml_f="49281" txt_i="30632" txt_f="30647"> Dose increased</offsets></td><td align="center"><offsets xml_i="49305" xml_f="49306" txt_i="30648" txt_f="30649">0</offsets></td><td align="center"><offsets xml_i="49330" xml_f="49331" txt_i="30650" txt_f="30651">0</offsets></td><td align="center"><offsets xml_i="49355" xml_f="49356" txt_i="30652" txt_f="30653">0</offsets></td><td align="center"><offsets xml_i="49380" xml_f="49381" txt_i="30654" txt_f="30655">0</offsets></td></tr><tr><td align="left"><offsets xml_i="49412" xml_f="49425" txt_i="30656" txt_f="30669"> Dose reduced</offsets></td><td align="center"><offsets xml_i="49449" xml_f="49450" txt_i="30670" txt_f="30671">0</offsets></td><td align="center"><offsets xml_i="49474" xml_f="49481" txt_i="30672" txt_f="30679">1 (3.7)</offsets></td><td align="center"><offsets xml_i="49505" xml_f="49506" txt_i="30680" txt_f="30681">0</offsets></td><td align="center"><offsets xml_i="49530" xml_f="49537" txt_i="30682" txt_f="30689">1 (2.3)</offsets></td></tr><tr><td align="left"><offsets xml_i="49568" xml_f="49585" txt_i="30690" txt_f="30707"> Dose not changed</offsets></td><td align="center"><offsets xml_i="49609" xml_f="49616" txt_i="30708" txt_f="30715">3 (100)</offsets></td><td align="center"><offsets xml_i="49640" xml_f="49649" txt_i="30716" txt_f="30725">23 (85.2)</offsets></td><td align="center"><offsets xml_i="49673" xml_f="49681" txt_i="30726" txt_f="30734">8 (88.9)</offsets></td><td align="center"><offsets xml_i="49705" xml_f="49714" txt_i="30735" txt_f="30744">42 (95.5)</offsets></td></tr><tr><td align="left"><offsets xml_i="49745" xml_f="49762" txt_i="30745" txt_f="30762"> Dose interrupted</offsets></td><td align="center"><offsets xml_i="49786" xml_f="49787" txt_i="30763" txt_f="30764">0</offsets></td><td align="center"><offsets xml_i="49811" xml_f="49812" txt_i="30765" txt_f="30766">0</offsets></td><td align="center"><offsets xml_i="49836" xml_f="49837" txt_i="30767" txt_f="30768">0</offsets></td><td align="center"><offsets xml_i="49861" xml_f="49862" txt_i="30769" txt_f="30770">0</offsets></td></tr><tr><td align="left"><offsets xml_i="49893" xml_f="49908" txt_i="30771" txt_f="30786"> Dose withdrawn</offsets></td><td align="center"><offsets xml_i="49932" xml_f="49933" txt_i="30787" txt_f="30788">0</offsets></td><td align="center"><offsets xml_i="49957" xml_f="49964" txt_i="30789" txt_f="30796">1 (3.7)</offsets></td><td align="center"><offsets xml_i="49988" xml_f="49989" txt_i="30797" txt_f="30798">0</offsets></td><td align="center"><offsets xml_i="50013" xml_f="50020" txt_i="30799" txt_f="30806">1 (2.3)</offsets></td></tr><tr><td align="left"><offsets xml_i="50051" xml_f="50066" txt_i="30807" txt_f="30822"> Not applicable</offsets></td><td align="center"><offsets xml_i="50090" xml_f="50091" txt_i="30823" txt_f="30824">0</offsets></td><td align="center"><offsets xml_i="50115" xml_f="50122" txt_i="30825" txt_f="30832">2 (7.4)</offsets></td><td align="center"><offsets xml_i="50146" xml_f="50154" txt_i="30833" txt_f="30841">1 (11.1)</offsets></td><td align="center"><offsets xml_i="50178" xml_f="50179" txt_i="30842" txt_f="30843">0</offsets></td></tr><tr><td align="left"><offsets xml_i="50210" xml_f="50233" txt_i="30844" txt_f="30867"> Led to discontinuation</offsets></td><td align="center"><offsets xml_i="50257" xml_f="50258" txt_i="30868" txt_f="30869">0</offsets></td><td align="center"><offsets xml_i="50282" xml_f="50289" txt_i="30870" txt_f="30877">1 (3.7)</offsets></td><td align="center"><offsets xml_i="50313" xml_f="50314" txt_i="30878" txt_f="30879">0</offsets></td><td align="center"><offsets xml_i="50338" xml_f="50345" txt_i="30880" txt_f="30887">1 (2.3)</offsets></td></tr></tbody></table><table-wrap-foot><fn id="tf10"><label><sup><offsets xml_i="50414" xml_f="50415" txt_i="30888" txt_f="30889">*</offsets></sup></label><p><offsets xml_i="50432" xml_f="50525" txt_i="30889" txt_f="30982">Includes adverse events with preferred terms insomnia, initial insomnia, and middle insomnia.</offsets></p></fn><fn id="tf11"><label><sup><offsets xml_i="50560" xml_f="50561" txt_i="30983" txt_f="30984">†</offsets></sup></label><p><offsets xml_i="50578" xml_f="51226" txt_i="30984" txt_f="31632">Overlapping events with different preferred terms were counted as multiple events. If a participant had multiple events of the same type that were not overlapping or adjacent in time, the durations were averaged and summary statistics were based on average durations. Event duration was the number of days from the onset of the event while on the study drug until the earlier of the end date of the event or the date of the last dose +3 days. If the date of the last dose was missing, the date of the last day of study was used. Events that either overlapped or were adjacent in time were merged into one event only when calculating event duration.</offsets></p></fn><fn id="tf12"><label><sup><offsets xml_i="51261" xml_f="51262" txt_i="31633" txt_f="31634">‡</offsets></sup></label><p><offsets xml_i="51279" xml_f="51351" txt_i="31634" txt_f="31706">Calculated as follows: (onset day of first event–date of first dose) +1.</offsets></p></fn><fn id="tf13"><label><sup><offsets xml_i="51386" xml_f="51387" txt_i="31707" txt_f="31708">§</offsets></sup></label><p><offsets xml_i="51404" xml_f="51658" txt_i="31708" txt_f="31962">Events having a resolution date on or before the participant's last dose date +3 days; if the last event of overlapping or adjacent adverse events of the same type was ongoing, the other event was not counted as resolved even if it had a resolution date.</offsets></p></fn><fn id="tf14"><label><sup><offsets xml_i="51693" xml_f="51694" txt_i="31963" txt_f="31964">¶</offsets></sup></label><p><offsets xml_i="51711" xml_f="51928" txt_i="31964" txt_f="32181">Includes adverse events without a resolution date; percentages are based on the number of treatment-emergent events, excluding from the denominator overlapping or adjacent events where a later event was still ongoing.</offsets></p></fn><fn id="tf15"><label><sup><offsets xml_i="51963" xml_f="51964" txt_i="32182" txt_f="32183">£</offsets></sup></label><p><offsets xml_i="51981" xml_f="52050" txt_i="32183" txt_f="32252">Percentages based on the number of treatment-emergent adverse events.</offsets></p></fn><fn id="tf16"><p><offsets xml_i="52076" xml_f="52129" txt_i="32253" txt_f="32306">MAS, mixed amphetamine salts; SD, standard deviation.</offsets></p></fn></table-wrap-foot></table-wrap><p><offsets xml_i="52172" xml_f="52477" txt_i="32307" txt_f="32612">No participant in the SHP465 MAS group experienced a psychiatric TEAE that was deemed to be of special interest (e.g., psychosis/mania, suicidal events, aggression, and other events); three participants in the placebo group experienced psychiatric TEAEs deemed to be of special interest (psychosis/mania, </offsets><italic><offsets xml_i="52485" xml_f="52486" txt_i="32612" txt_f="32613">n</offsets></italic><offsets xml_i="52495" xml_f="52518" txt_i="32613" txt_f="32636"> = 1; suicidal events, </offsets><italic><offsets xml_i="52526" xml_f="52527" txt_i="32636" txt_f="32637">n</offsets></italic><offsets xml_i="52536" xml_f="52542" txt_i="32637" txt_f="32643"> = 2).</offsets></p><p><offsets xml_i="52549" xml_f="52683" txt_i="32644" txt_f="32778">Mean increases in pulse, diastolic blood pressure, and systolic blood pressure in participants treated with SHP465 MAS were observed (</offsets><xref ref-type="table" rid="T2"><offsets xml_i="52715" xml_f="52722" txt_i="32778" txt_f="32785">Table 2</offsets></xref><offsets xml_i="52729" xml_f="52897" txt_i="32785" txt_f="32953">). The frequency of potentially clinically significant outliers at any time during treatment in pulse and blood pressure was greater with SHP465 MAS than with placebo (</offsets><xref ref-type="table" rid="T2"><offsets xml_i="52929" xml_f="52936" txt_i="32953" txt_f="32960">Table 2</offsets></xref><offsets xml_i="52943" xml_f="53256" txt_i="32960" txt_f="33273">). On the ECG, the mean ± SD change from baseline in the Fridericia-corrected QT (QTcF) interval was −2.9 ± 13.11 msec with placebo and 0.3 ± 13.83 msec with SHP465 MAS at the final on-treatment assessment. A QTcF interval ≥500 msec or an increase in QTcF interval of ≥60 msec was not observed in any participant.</offsets></p><p><offsets xml_i="53263" xml_f="53415" txt_i="33274" txt_f="33426">Mean increases in weight and BMI were observed with placebo, whereas mean decreases were observed with SHP465 MAS at the final on-treatment assessment (</offsets><xref ref-type="table" rid="T2"><offsets xml_i="53447" xml_f="53454" txt_i="33426" txt_f="33433">Table 2</offsets></xref><offsets xml_i="53461" xml_f="53561" txt_i="33433" txt_f="33533">). The frequency of weight loss of ≥7% from baseline was greater with SHP465 MAS than with placebo (</offsets><xref ref-type="table" rid="T2"><offsets xml_i="53593" xml_f="53600" txt_i="33533" txt_f="33540">Table 2</offsets></xref><offsets xml_i="53607" xml_f="53609" txt_i="33540" txt_f="33542">).</offsets></p><p><offsets xml_i="53616" xml_f="54040" txt_i="33543" txt_f="33967">In the C-SSRS assessment, one participant in the placebo group responded yes to the nonspecific activity suicide thoughts item within the suicidal ideation category. Another participant in the placebo group responded yes to the nonsuicidal self-injurious behavior item of the suicidal behavior category of the C-SSRS; the behavior was not considered suicidal; therefore, the participant was allowed to continue in the study.</offsets></p></sec></sec><sec sec-type="discussion" id="s014"><title><offsets xml_i="54100" xml_f="54110" txt_i="33970" txt_f="33980">Discussion</offsets></title><p><offsets xml_i="54121" xml_f="55036" txt_i="33981" txt_f="34896">In this phase 3 dose-optimization study, SHP465 MAS demonstrated superiority over placebo in the treatment of children and adolescents with ADHD, as measured by the primary efficacy endpoint (reductions in ADHD-RS-IV total score) and the key secondary endpoint (CGI-I score). The superiority of SHP465 MAS was supported by sensitivity analyses for ADHD-RS-IV total score and CGI-I score and by improvement on other secondary efficacy endpoints (ADHD-RS-IV subscale score reductions and dichotomized improvement on the CGI-I). These findings suggest that SHP465 MAS, which contains three types of drug-releasing beads—an immediate-release bead and two different types of DR beads, is an efficacious treatment option in children and adolescents with ADHD. The efficacy of SHP465 MAS in children and adolescents with ADHD that was observed in this study is consistent with findings in adults with ADHD (Spencer et al. </offsets><xref rid="B17" ref-type="bibr"><offsets xml_i="55068" xml_f="55072" txt_i="34896" txt_f="34900">2008</offsets></xref><offsets xml_i="55079" xml_f="55094" txt_i="34900" txt_f="34915">; Frick et al. </offsets><xref rid="B9" ref-type="bibr"><offsets xml_i="55125" xml_f="55129" txt_i="34915" txt_f="34919">2017</offsets></xref><offsets xml_i="55136" xml_f="55235" txt_i="34919" txt_f="35018">) and for other long-acting psychostimulants in children and adolescents with ADHD (Spencer et al. </offsets><xref rid="B16" ref-type="bibr"><offsets xml_i="55267" xml_f="55271" txt_i="35018" txt_f="35022">2006</offsets></xref><offsets xml_i="55278" xml_f="55296" txt_i="35022" txt_f="35040">; Maneeton et al. </offsets><xref rid="B12" ref-type="bibr"><offsets xml_i="55328" xml_f="55332" txt_i="35040" txt_f="35044">2015</offsets></xref><offsets xml_i="55339" xml_f="55356" txt_i="35044" txt_f="35061">; Storebo et al. </offsets><xref rid="B20" ref-type="bibr"><offsets xml_i="55388" xml_f="55392" txt_i="35061" txt_f="35065">2015</offsets></xref><offsets xml_i="55399" xml_f="55401" txt_i="35065" txt_f="35067">).</offsets></p><p><offsets xml_i="55408" xml_f="55921" txt_i="35068" txt_f="35581">The magnitude of treatment effect with SHP465 MAS observed in this study cannot be directly compared with psychostimulant effects reported in other studies due to differences in study design (including patient enrollment criteria, drug dose, and treatment length). However, the magnitude of ADHD-RS-IV total score reductions with SHP465 MAS in this study, which occurred after 2 weeks of dose maintenance, was within a range observed for other long-acting psychostimulants from individual studies (Spencer et al. </offsets><xref rid="B16" ref-type="bibr"><offsets xml_i="55953" xml_f="55957" txt_i="35581" txt_f="35585">2006</offsets></xref><offsets xml_i="55964" xml_f="55983" txt_i="35585" txt_f="35604">; Biederman et al. </offsets><xref rid="B2" ref-type="bibr"><offsets xml_i="56014" xml_f="56018" txt_i="35604" txt_f="35608">2007</offsets></xref><offsets xml_i="56025" xml_f="56042" txt_i="35608" txt_f="35625">; Newcorn et al. </offsets><xref rid="B13" ref-type="bibr"><offsets xml_i="56074" xml_f="56078" txt_i="35625" txt_f="35629">2008</offsets></xref><offsets xml_i="56085" xml_f="56103" txt_i="35629" txt_f="35647">; Findling et al. </offsets><xref rid="B8" ref-type="bibr"><offsets xml_i="56134" xml_f="56138" txt_i="35647" txt_f="35651">2011</offsets></xref><offsets xml_i="56145" xml_f="56160" txt_i="35651" txt_f="35666">; Stein et al. </offsets><xref rid="B18" ref-type="bibr"><offsets xml_i="56192" xml_f="56196" txt_i="35666" txt_f="35670">2011</offsets></xref><offsets xml_i="56203" xml_f="56220" txt_i="35670" txt_f="35687">; Coghill et al. </offsets><xref rid="B5" ref-type="bibr"><offsets xml_i="56251" xml_f="56255" txt_i="35687" txt_f="35691">2013</offsets></xref><offsets xml_i="56262" xml_f="56395" txt_i="35691" txt_f="35824">) and the treatment difference versus placebo was within ranges reported in systematic reviews and/or meta-analyses (Maneeton et al. </offsets><xref rid="B12" ref-type="bibr"><offsets xml_i="56427" xml_f="56431" txt_i="35824" txt_f="35828">2015</offsets></xref><offsets xml_i="56438" xml_f="56455" txt_i="35828" txt_f="35845">; Storebo et al. </offsets><xref rid="B20" ref-type="bibr"><offsets xml_i="56487" xml_f="56491" txt_i="35845" txt_f="35849">2015</offsets></xref><offsets xml_i="56498" xml_f="56500" txt_i="35849" txt_f="35851">).</offsets></p><p><offsets xml_i="56507" xml_f="56654" txt_i="35852" txt_f="35999">The overall safety and tolerability profile of SHP465 MAS in this study was consistent with that of SHP465 MAS in adults with ADHD (Spencer et al. </offsets><xref rid="B17" ref-type="bibr"><offsets xml_i="56686" xml_f="56690" txt_i="35999" txt_f="36003">2008</offsets></xref><offsets xml_i="56697" xml_f="56712" txt_i="36003" txt_f="36018">; Frick et al. </offsets><xref rid="B9" ref-type="bibr"><offsets xml_i="56743" xml_f="56747" txt_i="36018" txt_f="36022">2017</offsets></xref><offsets xml_i="56754" xml_f="56854" txt_i="36022" txt_f="36122">) and with that of other long-acting psychostimulants in children and adolescents (Biederman et al. </offsets><xref rid="B3" ref-type="bibr"><offsets xml_i="56885" xml_f="56889" txt_i="36122" txt_f="36126">2002</offsets></xref><offsets xml_i="56896" xml_f="56913" txt_i="36126" txt_f="36143">; Spencer et al. </offsets><xref rid="B16" ref-type="bibr"><offsets xml_i="56945" xml_f="56949" txt_i="36143" txt_f="36147">2006</offsets></xref><offsets xml_i="56956" xml_f="56973" txt_i="36147" txt_f="36164">; Newcorn et al. </offsets><xref rid="B13" ref-type="bibr"><offsets xml_i="57005" xml_f="57009" txt_i="36164" txt_f="36168">2008</offsets></xref><offsets xml_i="57016" xml_f="57034" txt_i="36168" txt_f="36186">; Findling et al. </offsets><xref rid="B8" ref-type="bibr"><offsets xml_i="57065" xml_f="57069" txt_i="36186" txt_f="36190">2011</offsets></xref><offsets xml_i="57076" xml_f="57093" txt_i="36190" txt_f="36207">; Coghill et al. </offsets><xref rid="B5" ref-type="bibr"><offsets xml_i="57124" xml_f="57128" txt_i="36207" txt_f="36211">2013</offsets></xref><offsets xml_i="57135" xml_f="57534" txt_i="36211" txt_f="36610">). The most frequently reported TEAEs (those reported by ≥2% of participants in the SHP465 MAS treatment arm) were decreased appetite, headache, insomnia, irritability, nausea, weight decreased, dizziness, increased heart rate increased, upper abdominal pain, and upper respiratory tract infection. This pattern is consistent with reports on adults with ADHD treated with SHP465 MAS (Spencer et al. </offsets><xref rid="B17" ref-type="bibr"><offsets xml_i="57566" xml_f="57570" txt_i="36610" txt_f="36614">2008</offsets></xref><offsets xml_i="57577" xml_f="57592" txt_i="36614" txt_f="36629">; Frick et al. </offsets><xref rid="B9" ref-type="bibr"><offsets xml_i="57623" xml_f="57627" txt_i="36629" txt_f="36633">2017</offsets></xref><offsets xml_i="57634" xml_f="57770" txt_i="36633" txt_f="36769">). These TEAEs have also been reported in children and/or adolescents treated with other long-acting psychostimulants (Biederman et al. </offsets><xref rid="B3" ref-type="bibr"><offsets xml_i="57801" xml_f="57805" txt_i="36769" txt_f="36773">2002</offsets></xref><offsets xml_i="57812" xml_f="57829" txt_i="36773" txt_f="36790">; Spencer et al. </offsets><xref rid="B16" ref-type="bibr"><offsets xml_i="57861" xml_f="57865" txt_i="36790" txt_f="36794">2006</offsets></xref><offsets xml_i="57872" xml_f="57889" txt_i="36794" txt_f="36811">; Newcorn et al. </offsets><xref rid="B13" ref-type="bibr"><offsets xml_i="57921" xml_f="57925" txt_i="36811" txt_f="36815">2008</offsets></xref><offsets xml_i="57932" xml_f="57950" txt_i="36815" txt_f="36833">; Findling et al. </offsets><xref rid="B8" ref-type="bibr"><offsets xml_i="57981" xml_f="57985" txt_i="36833" txt_f="36837">2011</offsets></xref><offsets xml_i="57992" xml_f="58009" txt_i="36837" txt_f="36854">; Coghill et al. </offsets><xref rid="B5" ref-type="bibr"><offsets xml_i="58040" xml_f="58044" txt_i="36854" txt_f="36858">2013</offsets></xref><offsets xml_i="58051" xml_f="58053" txt_i="36858" txt_f="36860">).</offsets></p><p><offsets xml_i="58060" xml_f="58335" txt_i="36861" txt_f="37136">The two most frequently reported TEAEs that occurred in participants randomized to SHP465 MAS, decreased appetite and insomnia, are also among the most frequently reported TEAEs in children and/or adolescents treated with other long-acting psychostimulants (Biederman et al. </offsets><xref rid="B3" ref-type="bibr"><offsets xml_i="58366" xml_f="58370" txt_i="37136" txt_f="37140">2002</offsets></xref><offsets xml_i="58377" xml_f="58379" txt_i="37140" txt_f="37142">, </offsets><xref rid="B2" ref-type="bibr"><offsets xml_i="58410" xml_f="58414" txt_i="37142" txt_f="37146">2007</offsets></xref><offsets xml_i="58421" xml_f="58438" txt_i="37146" txt_f="37163">; Spencer et al. </offsets><xref rid="B16" ref-type="bibr"><offsets xml_i="58470" xml_f="58474" txt_i="37163" txt_f="37167">2006</offsets></xref><offsets xml_i="58481" xml_f="58498" txt_i="37167" txt_f="37184">; Newcorn et al. </offsets><xref rid="B13" ref-type="bibr"><offsets xml_i="58530" xml_f="58534" txt_i="37184" txt_f="37188">2008</offsets></xref><offsets xml_i="58541" xml_f="58559" txt_i="37188" txt_f="37206">; Findling et al. </offsets><xref rid="B8" ref-type="bibr"><offsets xml_i="58590" xml_f="58594" txt_i="37206" txt_f="37210">2011</offsets></xref><offsets xml_i="58601" xml_f="58618" txt_i="37210" txt_f="37227">; Coghill et al. </offsets><xref rid="B5" ref-type="bibr"><offsets xml_i="58649" xml_f="58653" txt_i="37227" txt_f="37231">2013</offsets></xref><offsets xml_i="58660" xml_f="58805" txt_i="37231" txt_f="37376">). The frequency of decreased appetite/anorexia as a TEAE has been reported to range from 27.3% to 49.3% with lisdexamfetamine (Biederman et al. </offsets><xref rid="B2" ref-type="bibr"><offsets xml_i="58836" xml_f="58840" txt_i="37376" txt_f="37380">2007</offsets></xref><offsets xml_i="58847" xml_f="58865" txt_i="37380" txt_f="37398">; Findling et al. </offsets><xref rid="B8" ref-type="bibr"><offsets xml_i="58896" xml_f="58900" txt_i="37398" txt_f="37402">2011</offsets></xref><offsets xml_i="58907" xml_f="58924" txt_i="37402" txt_f="37419">; Coghill et al. </offsets><xref rid="B5" ref-type="bibr"><offsets xml_i="58955" xml_f="58959" txt_i="37419" txt_f="37423">2013</offsets></xref><offsets xml_i="58966" xml_f="59079" txt_i="37423" txt_f="37536">), from 17% to 20.7% with osmotic controlled-release oral delivery system (OROS) methylphenidate (Newcorn et al. </offsets><xref rid="B13" ref-type="bibr"><offsets xml_i="59111" xml_f="59115" txt_i="37536" txt_f="37540">2008</offsets></xref><offsets xml_i="59122" xml_f="59139" txt_i="37540" txt_f="37557">; Coghill et al. </offsets><xref rid="B5" ref-type="bibr"><offsets xml_i="59170" xml_f="59174" txt_i="37557" txt_f="37561">2013</offsets></xref><offsets xml_i="59181" xml_f="59252" txt_i="37561" txt_f="37632">), and from 21.9% to 44.8% with extended-release MAS (Biederman et al. </offsets><xref rid="B3" ref-type="bibr"><offsets xml_i="59283" xml_f="59287" txt_i="37632" txt_f="37636">2002</offsets></xref><offsets xml_i="59294" xml_f="59311" txt_i="37636" txt_f="37653">; Spencer et al. </offsets><xref rid="B16" ref-type="bibr"><offsets xml_i="59343" xml_f="59347" txt_i="37653" txt_f="37657">2006</offsets></xref><offsets xml_i="59354" xml_f="59474" txt_i="37657" txt_f="37777">). Rates of insomnia-related TEAEs have been reported to range from 9% to 24.7% with lisdexamfetamine (Biederman et al. </offsets><xref rid="B2" ref-type="bibr"><offsets xml_i="59505" xml_f="59509" txt_i="37777" txt_f="37781">2007</offsets></xref><offsets xml_i="59516" xml_f="59534" txt_i="37781" txt_f="37799">; Findling et al. </offsets><xref rid="B8" ref-type="bibr"><offsets xml_i="59565" xml_f="59569" txt_i="37799" txt_f="37803">2011</offsets></xref><offsets xml_i="59576" xml_f="59593" txt_i="37803" txt_f="37820">; Coghill et al. </offsets><xref rid="B5" ref-type="bibr"><offsets xml_i="59624" xml_f="59628" txt_i="37820" txt_f="37824">2013</offsets></xref><offsets xml_i="59635" xml_f="59698" txt_i="37824" txt_f="37887">), from 13% to 14.4% with OROS methylphenidate (Newcorn et al. </offsets><xref rid="B13" ref-type="bibr"><offsets xml_i="59730" xml_f="59734" txt_i="37887" txt_f="37891">2008</offsets></xref><offsets xml_i="59741" xml_f="59758" txt_i="37891" txt_f="37908">; Coghill et al. </offsets><xref rid="B5" ref-type="bibr"><offsets xml_i="59789" xml_f="59793" txt_i="37908" txt_f="37912">2013</offsets></xref><offsets xml_i="59800" xml_f="59870" txt_i="37912" txt_f="37982">), and from 8.9% to 17.5% with extended-release MAS (Biederman et al. </offsets><xref rid="B3" ref-type="bibr"><offsets xml_i="59901" xml_f="59905" txt_i="37982" txt_f="37986">2002</offsets></xref><offsets xml_i="59912" xml_f="59929" txt_i="37986" txt_f="38003">; Spencer et al. </offsets><xref rid="B16" ref-type="bibr"><offsets xml_i="59961" xml_f="59965" txt_i="38003" txt_f="38007">2006</offsets></xref><offsets xml_i="59972" xml_f="59974" txt_i="38007" txt_f="38009">).</offsets></p><p><offsets xml_i="59981" xml_f="60184" txt_i="38010" txt_f="38213">It is noteworthy that the overall frequency of insomnia as a TEAE was lower in this study (16.7% overall) than in the two SHP465 MAS studies on adults with ADHD (41.7% and 29.2% overall) (Spencer et al. </offsets><xref rid="B17" ref-type="bibr"><offsets xml_i="60216" xml_f="60220" txt_i="38213" txt_f="38217">2008</offsets></xref><offsets xml_i="60227" xml_f="60242" txt_i="38217" txt_f="38232">; Frick et al. </offsets><xref rid="B9" ref-type="bibr"><offsets xml_i="60273" xml_f="60277" txt_i="38232" txt_f="38236">2017</offsets></xref><offsets xml_i="60284" xml_f="60600" txt_i="38236" txt_f="38552">), possibly because of the lower SHP465 MAS doses used in this study. Compared with placebo, SHP465 MAS was associated with increases in pulse and blood pressure and with decreases in body weight. A similar pattern of changes in vital signs and weight has been reported with SHP465 MAS in adults with ADHD (Spencer e</offsets><xref rid="B17" ref-type="bibr"><offsets xml_i="60632" xml_f="60636" txt_i="38552" txt_f="38556">2008</offsets></xref><offsets xml_i="60643" xml_f="60658" txt_i="38556" txt_f="38571">; Frick et al. </offsets><xref rid="B9" ref-type="bibr"><offsets xml_i="60689" xml_f="60693" txt_i="38571" txt_f="38575">2017</offsets></xref><offsets xml_i="60700" xml_f="60803" txt_i="38575" txt_f="38678">) and with other long-acting psychostimulants in children and/or adolescents with ADHD (Spencer et al. </offsets><xref rid="B16" ref-type="bibr"><offsets xml_i="60835" xml_f="60839" txt_i="38678" txt_f="38682">2006</offsets></xref><offsets xml_i="60846" xml_f="60863" txt_i="38682" txt_f="38699">; Newcorn et al. </offsets><xref rid="B13" ref-type="bibr"><offsets xml_i="60895" xml_f="60899" txt_i="38699" txt_f="38703">2008</offsets></xref><offsets xml_i="60906" xml_f="60924" txt_i="38703" txt_f="38721">; Findling et al. </offsets><xref rid="B8" ref-type="bibr"><offsets xml_i="60955" xml_f="60959" txt_i="38721" txt_f="38725">2011</offsets></xref><offsets xml_i="60966" xml_f="60983" txt_i="38725" txt_f="38742">; Coghill et al. </offsets><xref rid="B5" ref-type="bibr"><offsets xml_i="61014" xml_f="61018" txt_i="38742" txt_f="38746">2013</offsets></xref><offsets xml_i="61025" xml_f="61027" txt_i="38746" txt_f="38748">).</offsets></p><sec id="s015"><title><offsets xml_i="61053" xml_f="61064" txt_i="38749" txt_f="38760">Limitations</offsets></title><p><offsets xml_i="61075" xml_f="61675" txt_i="38761" txt_f="39361">The study population was primarily male and white. As such, it is unknown how these data would generalize to a more diverse treatment population. Although the study was not powered to compare subgroup differences, exploratory analyses suggested that the primary efficacy findings by race and gender were generally in agreement with the overall results. Findings for the secondary efficacy endpoints (dichotomized CGI-I and ADHD-RS-IV subscales) and from the exploratory analyses should be interpreted in light of the fact that they were not included in the testing hierarchy. Therefore, the reported </offsets><italic><offsets xml_i="61683" xml_f="61684" txt_i="39361" txt_f="39362">p</offsets></italic><offsets xml_i="61693" xml_f="61937" txt_i="39362" txt_f="39606">-values for these endpoints are nominal (unadjusted) and provided for descriptive purposes only. In addition, the long-term safety and tolerability of SHP465 MAS cannot be determined from these data given the short 4-week duration of the study.</offsets></p></sec></sec><sec sec-type="conclusions" id="s016"><title><offsets xml_i="61998" xml_f="62009" txt_i="39609" txt_f="39620">Conclusions</offsets></title><p><offsets xml_i="62020" xml_f="62672" txt_i="39621" txt_f="40273">SHP465 MAS demonstrated superiority over placebo in improving ADHD core symptoms and global functioning in children and adolescents with ADHD. The safety and tolerability profile of SHP465 MAS was similar to that observed in adults and of other long-acting psychostimulants. Based on this study, the SHP465 MAS starting dose in pediatric patients (aged 13–17 years) is suggested to be 12.5 mg once daily in the morning. The dosage may be adjusted in increments of 12.5 mg no sooner than weekly up to the maximum dose of 25 mg per day based on efficacy, tolerability, and safety. SHP465 MAS is not approved for use in children aged 12 years and younger.</offsets></p></sec><sec id="s017"><title><offsets xml_i="62704" xml_f="62725" txt_i="40275" txt_f="40296">Clinical Significance</offsets></title><p><offsets xml_i="62736" xml_f="63385" txt_i="40297" txt_f="40946">Some prescribers may supplement a long-acting psychostimulant with an immediate-release short-acting psychostimulant later in the day for children and adolescents with attention-deficit/hyperactivity disorder (ADHD). Therefore, there is a need for once-daily psychostimulant medications. SHP465 mixed amphetamine salts (MAS) is a long-acting psychostimulant for the treatment of ADHD. The findings of this study indicate that SHP465 MAS is superior over placebo in improving ADHD symptoms and global functioning in children and adolescents with ADHD, with a safety and tolerability profile consistent with that of other long-acting psychostimulants.</offsets></p></sec><sec sec-type="supplementary-material"><title><offsets xml_i="63441" xml_f="63463" txt_i="40948" txt_f="40970">Supplementary Material</offsets></title><supplementary-material content-type="local-data" id="SD1"><caption><title><offsets xml_i="63546" xml_f="63563" txt_i="40971" txt_f="40988">Supplemental data</offsets></title></caption><media mimetype="application" mime-subtype="pdf" xlink:href="Supp_Table1.pdf" orientation="portrait" xlink:type="simple" id="d38e1883" position="anchor"></media></supplementary-material><supplementary-material content-type="local-data" id="SD2"><caption><title><offsets xml_i="63842" xml_f="63859" txt_i="40989" txt_f="41006">Supplemental data</offsets></title></caption><media mimetype="application" mime-subtype="pdf" xlink:href="Supp_Table2.pdf" orientation="portrait" xlink:type="simple" id="d38e1888" position="anchor"></media></supplementary-material></sec></body><back><sec id="s018" sec-type="ack"><title>Acknowledgments</title><p>Under the direction of the authors, writing assistance was provided by Madhura Mehta, PhD, and Craig Slawecki, PhD, employees of Complete Healthcare Communications, LLC (West Chester, PA). Editorial assistance in the form of proofreading, copyediting, and fact checking was also provided by Complete Healthcare Communications, LLC. Shailesh Desai, PhD, from Shire Development, LLC, also reviewed and edited the manuscript for scientific accuracy. Statistical analysis of the data was conducted by Dr. Yan (an employee of Shire).</p></sec><sec id="s019"><title>Disclosures</title><p>M.B. has served as a speaker for Alkermes, Arbor, Lundbeck, NEOS, Otsuka, Rhodes, Shire, Silenor, Sunovion, Supernus, Takeda, TEVA, and TRIS; has received research support from Arbor, Shire, TEVA, and TRIS; and has served on advisory boards for NEOS, Otsuka, Shire, Supernus, TEVA, and TRIS. A.C.C. has served on advisory boards for Arbor, Ironshore, Neos, Neurovance, NLS-1 Pharma, Noven, Pfizer, Rhodes, and Tris; has been a consultant for Arbor, Ironshore, Neos, Neurovance, Purdue, Rhodes, Shire, and Sunovion; has been a speaker at Arbor, Neos, Pfizer, Shire, and Tris; has received research support from Alcobra, Arbor, Eli Lilly, Forest, Ironshore, Lundbeck, Medgenics, Neos, Neurovance, Noven, Otsuka, Pearson, Pfizer, Purdue, Rhodes, Shire, Sunovion, Tris, and Akili; and has received writing support from Arbor, Ironshore, Neos, Pfizer, Rhodes, Shire, and Tris. M.G. has served on the speakers bureau for Shire and receives research support from Allergan, Lundbeck, Medgenics, Shire, Sunovion, Supernus, and Takeda. M.Y., B.Y., M.J., and B.R. are employees of Shire and hold stock and/or stock options in Shire.</p></sec><ref-list content-type="parsed"><title>References</title><ref id="B1"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Atkinson</surname><given-names>M</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Hollis</surname><given-names>C</given-names></name></person-group>: <article-title>NICE guideline: Attention deficit hyperactivity disorder</article-title>. <source>Arch Dis Child Educ Pract Ed</source>
<volume>95</volume>:<fpage>24</fpage>–<lpage>27</lpage>, <year>2010</year><pub-id pub-id-type="pmid">20145015</pub-id></mixed-citation></ref><ref id="B2"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Biederman</surname><given-names>J</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Krishnan</surname><given-names>S</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>McGough</surname><given-names>JJ</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Findling</surname><given-names>RL</given-names></name></person-group>: <article-title>Efficacy and tolerability of lisdexamfetamine dimesylate (NRP-104) in children with attention-deficit/hyperactivity disorder: A phase III, multicenter, randomized, double-blind, forced-dose, parallel-group study</article-title>. <source>Clin Ther</source>
<volume>29</volume>:<fpage>450</fpage>–<lpage>463</lpage>, <year>2007</year><pub-id pub-id-type="pmid">17577466</pub-id></mixed-citation></ref><ref id="B3"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Biederman</surname><given-names>J</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Lopez</surname><given-names>FA</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Boellner</surname><given-names>SW</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Chandler</surname><given-names>MC</given-names></name></person-group>: <article-title>A randomized, double-blind, placebo-controlled, parallel-group study of SLI381 (Adderall XR) in children with attention-deficit/hyperactivity disorder</article-title>. <source>Pediatrics</source>
<volume>110</volume>:<fpage>258</fpage>–<lpage>266</lpage>, <year>2002</year><pub-id pub-id-type="pmid">12165576</pub-id></mixed-citation></ref><ref id="B4"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Briars</surname><given-names>L</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Todd</surname><given-names>T</given-names></name></person-group>: <article-title>A review of pharmacological management of attention-deficit/hyperactivity disorder</article-title>. <source>J Pediatr Pharmacol Ther</source>
<volume>21</volume>:<fpage>192</fpage>–<lpage>206</lpage>, <year>2016</year><pub-id pub-id-type="pmid">27453697</pub-id></mixed-citation></ref><ref id="B5"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coghill</surname><given-names>D</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Banaschewski</surname><given-names>T</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Lecendreux</surname><given-names>M</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Soutullo</surname><given-names>C</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Johnson</surname><given-names>M</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Zuddas</surname><given-names>A</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Anderson</surname><given-names>C</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Civil</surname><given-names>R</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Higgins</surname><given-names>N</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Lyne</surname><given-names>A</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Squires</surname><given-names>L</given-names></name></person-group>: <article-title>European, randomized, phase 3 study of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/hyperactivity disorder</article-title>. <source>Eur Neuropsychopharmacol</source>
<volume>23</volume>:<fpage>1208</fpage>–<lpage>1218</lpage>, <year>2013</year><pub-id pub-id-type="pmid">23332456</pub-id></mixed-citation></ref><ref id="B6"><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Dupaul</surname><given-names>G</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Power</surname><given-names>T</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Anastopoulos</surname><given-names>A</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Reed</surname><given-names>R</given-names></name></person-group>: <source>ADHD Rating Scale-IV: Checklists, Norms, and Clinical Interpretation</source>. <publisher-loc>New York (New York)</publisher-loc>, <publisher-name>Guilford Press</publisher-name>, <year>1998</year></mixed-citation></ref><ref id="B7"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ermer</surname><given-names>JC</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Shojaei</surname><given-names>A</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Pennick</surname><given-names>M</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Anderson</surname><given-names>CS</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Silverberg</surname><given-names>A</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Youcha</surname><given-names>SH</given-names></name></person-group>: <article-title>Bioavailability of triple-bead mixed amphetamine salts compared with a dose-augmentation strategy of mixed amphetamine salts extended release plus mixed amphetamine salts immediate release</article-title>. <source>Curr Med Res Opin</source>
<volume>23</volume>:<fpage>1067</fpage>–<lpage>1075</lpage>, <year>2007</year><pub-id pub-id-type="pmid">17519073</pub-id></mixed-citation></ref><ref id="B8"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Findling</surname><given-names>RL</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Childress</surname><given-names>AC</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Cutler</surname><given-names>AJ</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Gasior</surname><given-names>M</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Hamdani</surname><given-names>M</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Ferreira-Cornwell</surname><given-names>MC</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Squires</surname><given-names>L</given-names></name></person-group>: <article-title>Efficacy and safety of lisdexamfetamine dimesylate in adolescents with attention-deficit/hyperactivity disorder</article-title>. <source>J Am Acad Child Adolesc Psychiatry</source>
<volume>50</volume>:<fpage>395</fpage>–<lpage>405</lpage>, <year>2011</year><pub-id pub-id-type="pmid">21421179</pub-id></mixed-citation></ref><ref id="B9"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frick</surname><given-names>G</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Yan</surname><given-names>B</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Adler</surname><given-names>LA</given-names></name></person-group>: <article-title>Triple-bead mixed amphetamine salts (SHP465) in adults with ADHD: Results of a phase 3, double-blind, randomized, forced-dose trial</article-title>. <source>J Atten Disord</source>
<year>2017</year> [Epub ahead of print]. DOI:<pub-id pub-id-type="doi">10.1177/1087054717696771</pub-id></mixed-citation></ref><ref id="B10"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Glenngard</surname><given-names>AH</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Hjelmgren</surname><given-names>J</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Thomsen</surname><given-names>PH</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Tvedten</surname><given-names>T</given-names></name></person-group>: <article-title>Patient preferences and willingness-to-pay for ADHD treatment with stimulants using discrete choice experiment (DCE) in Sweden, Denmark and Norway</article-title>. <source>Nord J Psychiatry</source>
<volume>67</volume>:<fpage>351</fpage>–<lpage>359</lpage>, <year>2013</year><pub-id pub-id-type="pmid">23245636</pub-id></mixed-citation></ref><ref id="B11"><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Guy</surname><given-names>W</given-names></name></person-group>: <collab>Clinical Global Impression (CGI)</collab>. <publisher-loc>Rockville (Maryland)</publisher-loc>, <publisher-name>U.S. Department of Health, Education, and Welfare</publisher-name>, <year>1976</year></mixed-citation></ref><ref id="B12"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maneeton</surname><given-names>B</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Maneeton</surname><given-names>N</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Likhitsathian</surname><given-names>S</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Suttajit</surname><given-names>S</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Narkpongphun</surname><given-names>A</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Srisurapanont</surname><given-names>M</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Woottiluk</surname><given-names>P</given-names></name></person-group>: <article-title>Comparative efficacy, acceptability, and tolerability of lisdexamfetamine in child and adolescent ADHD: A meta-analysis of randomized, controlled trials</article-title>. <source>Drug Des Devel Ther</source>
<volume>9</volume>:<fpage>1927</fpage>–<lpage>1936</lpage>, <year>2015</year></mixed-citation></ref><ref id="B13"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Newcorn</surname><given-names>JH</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Kratochvil</surname><given-names>CJ</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Allen</surname><given-names>AJ</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Casat</surname><given-names>CD</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Ruff</surname><given-names>DD</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Moore</surname><given-names>RJ</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Michelson</surname><given-names>D</given-names></name></person-group>; <collab>Atomoxetine/Methylphenidate Comparative Study Group</collab>: <article-title>Atomoxetine and osmotically released methylphenidate for the treatment of attention deficit hyperactivity disorder: Acute comparison and differential response</article-title>. <source>Am J Psychiatry</source>
<volume>165</volume>:<fpage>721</fpage>–<lpage>730</lpage>, <year>2008</year><pub-id pub-id-type="pmid">18281409</pub-id></mixed-citation></ref><ref id="B14"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pliszka</surname><given-names>S</given-names></name></person-group>: <article-title>Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder</article-title>. <source>J Am Acad Child Adolesc Psychiatry</source>
<volume>46</volume>:<fpage>894</fpage>–<lpage>921</lpage>, <year>2007</year><pub-id pub-id-type="pmid">17581453</pub-id></mixed-citation></ref><ref id="B15"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Posner</surname><given-names>K</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Brown</surname><given-names>GK</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Stanley</surname><given-names>B</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Brent</surname><given-names>DA</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Yershova</surname><given-names>KV</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Oquendo</surname><given-names>MA</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Currier</surname><given-names>GW</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Melvin</surname><given-names>GA</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Greenhill</surname><given-names>L</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Shen</surname><given-names>S</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Mann</surname><given-names>JJ</given-names></name></person-group>: <article-title>The Columbia-Suicide Severity Rating Scale: Initial validity and internal consistency findings from three multisite studies with adolescents and adults</article-title>. <source>Am J Psychiatry</source>
<volume>168</volume>:<fpage>1266</fpage>–<lpage>1277</lpage>, <year>2011</year><pub-id pub-id-type="pmid">22193671</pub-id></mixed-citation></ref><ref id="B16"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spencer</surname><given-names>TJ</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Abikoff</surname><given-names>HB</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Connor</surname><given-names>DF</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Biederman</surname><given-names>J</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Pliszka</surname><given-names>SR</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Boellner</surname><given-names>S</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Read</surname><given-names>SC</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Pratt</surname><given-names>R</given-names></name></person-group>: <article-title>Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of oppositional defiant disorder with or without comorbid attention-deficit/hyperactivity disorder in school-aged children and adolescents: A 4-week, multicenter, randomized, double-blind, parallel-group, placebo-controlled, forced-dose-escalation study</article-title>. <source>Clin Ther</source>
<volume>28</volume>:<fpage>402</fpage>–<lpage>418</lpage>, <year>2006</year><pub-id pub-id-type="pmid">16750455</pub-id></mixed-citation></ref><ref id="B17"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spencer</surname><given-names>TJ</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Adler</surname><given-names>LA</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Weisler</surname><given-names>RH</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Youcha</surname><given-names>SH</given-names></name></person-group>: <article-title>Triple-bead mixed amphetamine salts (SPD465), a novel, enhanced extended-release amphetamine formulation for the treatment of adults with ADHD: A randomized, double-blind, multicenter, placebo-controlled study</article-title>. <source>J Clin Psychiatry</source>
<volume>69</volume>:<fpage>1437</fpage>–<lpage>1448</lpage>, <year>2008</year><pub-id pub-id-type="pmid">19012813</pub-id></mixed-citation></ref><ref id="B18"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stein</surname><given-names>MA</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Waldman</surname><given-names>ID</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Charney</surname><given-names>E</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Aryal</surname><given-names>S</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Sable</surname><given-names>C</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Gruber</surname><given-names>R</given-names></name></person-group> and <person-group person-group-type="author"><name><surname>Newcorn</surname><given-names>JH</given-names></name></person-group>: <article-title>Dose effects and comparative effectiveness of extended release dexmethylphenidate and mixed amphetamine salts</article-title>. <source>J Child Adolesc Psychopharmacol</source>
<volume>21</volume>:<fpage>581</fpage>–<lpage>588</lpage>, <year>2011</year><pub-id pub-id-type="pmid">22136094</pub-id></mixed-citation></ref><ref id="B19"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Steinhoff</surname><given-names>KW</given-names></name></person-group>: <article-title>Attention-deficit/hyperactivity disorder: Medication treatment-dosing and duration of action</article-title>. <source>Am J Manag Care</source>
<volume>10</volume>:<fpage>S99</fpage>–<lpage>S106</lpage>, <year>2004</year><pub-id pub-id-type="pmid">15352536</pub-id></mixed-citation></ref><ref id="B20"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Storebo</surname><given-names>OJ</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Krogh</surname><given-names>HB</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Ramstad</surname><given-names>E</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Moreira-Maia</surname><given-names>CR</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Holmskov</surname><given-names>M</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Skoog</surname><given-names>M</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Nilausen</surname><given-names>TD</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Magnusson</surname><given-names>FL</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Zwi</surname><given-names>M</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Gillies</surname><given-names>D</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Rosendal</surname><given-names>S</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Groth</surname><given-names>C</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Rasmussen</surname><given-names>KB</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Gauci</surname><given-names>D</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Kirubakaran</surname><given-names>R</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Forsbol</surname><given-names>B</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Simonsen</surname><given-names>E</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Gluud</surname><given-names>C</given-names></name></person-group>: <article-title>Methylphenidate for attention-deficit/hyperactivity disorder in children and adolescents: Cochrane systematic review with meta-analyses and trial sequential analyses of randomised clinical trials</article-title>. <source>BMJ</source>
<volume>351</volume>:<fpage>h5203</fpage>, <year>2015</year><pub-id pub-id-type="pmid">26608309</pub-id></mixed-citation></ref><ref id="B21"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thomas</surname><given-names>M</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Rostain</surname><given-names>A</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Prevatt</surname><given-names>F</given-names></name></person-group>: <article-title>ADHD diagnosis and treatment in college students and young adults</article-title>. <source>Adolesc Med State Art Rev</source>
<volume>24</volume>:<fpage>659</fpage>–<lpage>679</lpage>, <year>2013</year><pub-id pub-id-type="pmid">24654555</pub-id></mixed-citation></ref></ref-list></back></article>